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Abstract 
Dendritic cells (DCs) are professional antigen presenting cells (APC) that orchestrate the immune 
response.  These cells play a major role in inducing primary immune response by activating naïve 
CD8
+
 and CD4
+
 T cells. In mice, CD8
+
 DC is the major DC subset that excels in priming CD8
+
 T 
cells to become cytotoxic T cells (CTL), critical to induce anti-tumour and anti-viral immunity. 
Human peripheral blood, lymphoid and nonlymphoid organs contain 3 major DC subsets, 
plasmacytoid dendritic cells (pDCs), CD1c
+
 and CD141
+
 myeloid DCs, each with distinct 
functional characteristics. Comparative transcriptome analysis enabled close alignment of human 
and mouse DC subsets. However translating the knowledge obtained from the mouse to the human 
DC system has been hampered by differences such as the expression of pathogen recognition 
receptors (PRR), which necessitate the study on human DC for functional characterisation. 
Functional studies of human DC subsets have been limited due to their rarity, technical challenging 
isolation procedures and a lack of in vitro models. To overcome this limitation, mouse models of 
human haematopoetic stem cell (HSC) engraftment have been used and are referred to as 
humanised mice.  
Humanised mouse model represent a powerful tool to study various key aspects of human immune 
function. Here we describe the development and characterization of HLA-A2 transgenic 
NOD/SCID/IL2rg null (NSG-A2) mice for their ability to support human cord blood (CB)-derived 
HSC engraftment and multilineage differentiation. NSG-A2 mice were capable of developing 
human myeloid DC and pDC, B cells, T cells and monocytes in bone marrow (BM), spleen, liver, 
lung and peripheral blood by 10-14wks post injection.  
Transcriptional analysis demonstrated close alignment of BM-derived DC subsets from humanised 
NSG-A2 mice with human blood and tissue DC. The immunoactivation potential of different toll-
like receptor (TLR) activators on human DC subsets in vivo was evaluated based on the expression 
of activation surface markers, differential gene expression using microarray and cytokine levels in 
serum by cytokine bead assay. All DC subsets purified from BM of humanised mice were capable 
of priming naïve antigen (Ag)-specific CD8
+
 T cells to elicit a polyfunctional T cell response 
(CD107a, TNFα, IFNγ, IL-2) against MART-1 peptide.  
Thus, NSG-A2 mice engrafted with human CB-derived HSC is a useful in vivo long-lived model to 
investigate the functional and phenotypical characteristics of human DC subsets in both in vitro and 
in vivo settings. This will also be a powerful model for preclinical studies to design and validate 
novel immunotherapies and vaccines. 
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Chapter 1: Introduction and literature review 
1.1 DC function 
DC are the key regulators of the immune system forming a network link between innate and 
adaptive immunity. DC are known as “professional” APC for their ability to capture Ag and present 
it in the context of major histocompatibility complex (MHC) molecules to stimulate naïve T cells.  
1.2 DC maturation 
DC maturation is a determining factor for the effectiveness of the induction of T cell response upon 
Ag uptake (1, 2).  In response to inflammatory mediators and “danger signals” released from 
damaged and infected cells, DC undergo a process of differentiation and activation (3). DC 
maturation is characterised by differentiation from Ag-capturing cells to a T cell priming cells. This 
is accompanied by the loss of endocytic receptors, increased efficiency in presentation of Ag by 
MHC molecules and upregulation of costimulatory molecules (such as CD80 and CD86) required 
for T cell activation (4-6). Matured DC also gains function to secrete polarising cytokines that will 
determine the type of immune response (Th1, Th2 and Th17) to be induced (7, 8).  
1.3 DC sensing 
DC are equipped with a diverse range of pathogen recognition receptors (PRR) that are capable of 
recognising structures conserved between microbial species, termed Pathogen Associated Molecular 
Pattern (PAMPs), and Damage Associated Molecular Pattern (DAMPs) to alert the immune system 
to infection or cell and tissue damage (9). The most extensively studied PRR is the TLR. TLR can 
be categorised into two groups according to their cellular location. Extracellular TLR (TLR1, 2, 4, 5, 
6) are specialised in recognising bacterial products, whereas intracellular TLR (TLR3, 7, 8, 9) are 
specialised in recognising various types of nucleic acids (10). C-type lectin receptors (CLR) also 
function as PRR by detecting PAMP carbohydrate structures (11). As opposed to TLR which 
mainly act to alert DC to infection or damaged cells, CLR are known to have additional functional 
properties that are associated with cell interaction (e.g. DC-SIGN (12), dectin-1(13), DCAL-1(14)) 
and Ag uptake (e.g. DEC205(15), CLEC9A (16)). The phagocytic properties of CLR have been of 
particular interest as potential targets to deliver Ag to DC for vaccine design (17) (to be discussed in 
more detail in section 1.4.2).   
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1.4 DC heterogeneity 
DC are comprised of heterogeneous subsets that differ in their location, phenotypes and specialised 
functions. DC can be classified into three principle groups: pDC, conventional dendritic cells (cDC) 
and inflammatory DC (18). Blood and lymphoid tissue contain pDC which can enter the lymph 
node via the blood circulation (18, 19). cDC can be further subdivided into lymphoid resident DC 
and non-lymphoid resident DC (migratory DC). Lymphoid resident DC are derived from the blood 
borne precursors that have differentiated into immature DC which have a sentinel function in the 
blood and lymphatics, surveying for pathogens (20-23). In contrast, migratory DC survey for Ag 
within peripheral tissues and migrate to the lymphoid tissues to present their Ag to the T cells (24). 
Inflammatory DC are unique DC subset derived from the monocyte precursor. This type of DC is 
absent under steady state conditions but appears only during infection or inflammatory conditions 
(25, 26).  The main focus in this project is the cDC subset.  
1.4.1 Mouse DC subsets 
1.4.1.1 pDC 
pDC express high levels of TLR 7 and 9 that these cells have been well characterised as the major 
producers of type 1 IFN following viral infection or TLR7 and TLR9 stimulation (27, 28). pDC also 
express both MHC Class I and MHC Class II as well as costimulatory molecules (e.g CD80 and 
CD86) that have been shown to prime both CD4
+
 (29) and CD8
+
 (30, 31) T cells. However they 
have been demonstrated to be inefficient in presenting exogenous Ag (29, 31) 
1.4.1.2 Lymphoid resident DC 
The lymphoid resident DC in mice have two functionally distinct subsets, CD8
+
 DC and CD8
-
 DC, 
which are distinguished by the expression of the CD8α surface marker. CD8- DC are efficient in 
MHC Class II presentation and drive T helper 2 (Th2) responses (32-34). CD8
+
 DC, unlike CD8
-
 
DC, are major producers of IL-12 (35) and are capable of taking up dead cells (36). In addition, the 
defining functional characteristic of CD8
+
 DC is its ability to efficiently present exogenous Ag 
through the MHC Class I pathway, a process known as cross-presentation (34, 36, 37), to activate 
the CD8
+ 
T cells to become CTL. This is a fundamental process by which Ag from tumour cells and 
virally infected cells other than DC can access the MHC class I pathway (38). In addition to cross-
presentation, there is evidence showing that CD8
+
 DC have higher expression of MHC I associated 
genes (e.g TAP1, TAP2, Sec61, Cystatin B and C) (32) and are major producers of IL-12 (39, 40) 
and IL-15 (41), two cytokines that play a role in the differentiation of CD8
+
 T cells (42, 43). The 
CLR, CLEC9A, and the chemokine receptor, XCR1, is exclusively expressed on CD8
+
 DC. 
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CLEC9A is required for acquisition of Ag from dead and dying cells and also regulates cross-
presentation (44, 45). The XCR1 ligand, named XCL1, is expressed on CD8
+
 T cells after antigen 
presentation. It is critical in the survival and differentiation of CD8
+
 CTL (46). This may suggest 
that CD8
+
 DC are intrinsically better at priming CD8
+
 T cells irrespective of cross-presentation. 
Furthermore, CD8
+
 DC have been shown to be the dominant DC subset playing a pivotal role in 
anti-tumour (47-49) and anti-viral immunity (50-54).  
1.4.1.3 Migratory DC 
Langerhan’s cells are the only DC found in the epidermis which play a critical role in tolerance 
induction (55, 56). In the dermis, DC subsets can be distinguished based on expression of CD11b 
and CD103 which are also found in other organs such as lung, liver and kidney (57). Despite the 
presence of three different DC subsets in the skin, CD103
+
 DC were the dominant migratory DC 
subset able to cross-present viral and self Ag to CD8
+
 T cells (58, 59). Interestingly, CD103
+
 DC 
share many attributes with CD8
+
 DC such as the ability to take up dead cells and responsiveness to 
TLR3 ligand (60). Transcriptomic analysis has demonstrated that these cells are closely related with 
common gene signatures not found in other DC subsets (61). In contrast, CD11b
+
 DC are more 
specialised at priming CD4
+
 T helper 17 (Th17) (62-64) and Th2 cells (65, 66). 
1.4.2 Human DC subsets 
The subset heterogeneity and functional specialisation of DC subsets is a common feature found in 
both mice and humans. However the functional characterisation of human DC subsets has been 
limited due to their rarity.  
1.4.2.1 pDC 
Similar to mouse pDC, human pDC preferentially express TLR 7 and TLR9 and produce large 
amount of type 1 IFN in response to binding of these TLR when exposed to viruses (67). pDC were 
initially thought to be important for innate immunity and to have minimal participation in Ag 
presentation to the T cells. There are several studies that have also shown that pDC are capable of 
priming CD4
+
 T cells (68)  and cross-presenting Ag to CD8
+
 T cells (69-72).  
1.4.2.2 Lymphoid resident DC 
 In humans, the two major lymphoid resident DC subsets are the CD141
+ 
DC and CD1c
+
 DC (73). 
There is now compelling evidence from several groups that the CD141
+
 DC subset is the human 
equivalent of the mouse CD8
+
 (and relatedly the CD103
+
 tissue resident) DC subset (74-79). 
CD141
+
 DC have overlapping phenotype, function and gene expression profiles with their mouse 
counterparts. They both share expression of the CLEC9A, XCR1, nectin-like protein, NECL2, and 
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also require transcriptional factors BATF3, IRF8, ID2 for their development. In addition, both cell 
subsets are efficient in cross-presentation, capturing dead cells and are major producers of IFNλ in 
response to TLR3 ligand (80).  Similar to the mouse counterpart, CD141
+
 DC also have higher 
expression of MHC Class I associated genes (TAP 1, TAP 2 and Sec61a) compared to CD1c
+
 DC 
(79).  
CD1c
+
 DC express all TLR except TLR9, which is expressed only in pDC and B cells in humans 
(81). They have been characterised as poor producers of IL-12 in response to E.coli (82). Our group 
have also demonstrated minimal IL-12 production by the CD1c
+
 DC compared with the CD141
+
 
DC in response to poly IC (TLR3 ligand) and a cytokine cocktail (IFNγ, TNF, IFNα and IL-1β) 
(79). However Nizzoli et al. (83) have demonstrated that CD1c
+
 DC are in fact the major producers 
of IL-12 in response to dual activation of TLR4 and 7/8 using LPS and R848, respectively. This 
suggests that CD1c
+
 DC requires multiple TLR activation to induce IL-12 production. In the mouse 
system, CD8
+
 DC were shown to be the major producers of IL-12, but study on human DC shows 
the secretion of IL-12 is not restricted to CD141
+
 DC but also can be secreted by CD1c
+
 DC (84, 
85). Furthermore CD1c
+
 DC have also been demonstrated to have cross-presenting abilities (86, 
87) . 
The differential expression of cytokines and chemokines between human DC subsets is also critical 
as it has been shown to be associated with activation of CD8
+
 T cells (88-90). Therefore these 
factors will be investigated in this study to understand if CD141
+
 DC are intrinsically better at 
priming CD8
+
 T cells irrespective of their cross-presenting ability.  
1.4.2.3 Human DC subsets and CD8
+
 T cell activation 
There is no question that all blood DC subsets can cross-present Ags to CD8
+
 T cells (91, 92), 
however what is not clear is how efficient each DC subsets are in cross-presentation.  Several 
comparative studies (74, 78, 79) have demonstrated that CD141
+
 DC was superior in cross-
presentation compared to other DC subsets (CD1c
+
 DC and pDC).  
Bachem et al. (74) conducted one of the first studies to compare the cross-presentation capacity for 
all 4 human blood DC subsets. This study concluded that CD141
+
 DC are the most superior cross-
presenting DC in human blood. However this study was conducted in the absence of any TLR 
stimulus which may not have been the optimal condition for other DC subsets to cross-present Ags. 
DC subsets have distinct TLR expression profiles that will differ in their sensitivity to particular 
adjuvants (81).  Jongbloed et al. (79) have activated DC with poly IC, which enhanced cross 
presentation in CD141
+
 DC but not in CD1c
+
 DC. CD141
+
 DC are known to express the highest 
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level of TLR3 compared to other human blood DC subsets, which could have biased towards 
improved cross-presentation by CD141
+
 DC. However they have also shown that CD1c
+
 DC, which 
highly express TLR4 (poorly expressed in CD141
+
 DC) did not enhance cross-presentation in the 
presence of LPS. This is supported by Crozat et al. (78), where appropriate TLR ligand was used for 
each DC subset and showed that CD141
+
 DC excelled in cross-presentation. 
There are several comparative studies (93, 94) that have questioned this notion and demonstrated 
that CD141
+
 DC, CD1c
+
 DC and pDC have similar efficiency in cross-presentation. Interestingly 
Nizolli et al. (83) have demonstrated that both CD141
+
 DC and CD1c
+
 DC subsets require 
combinational TLR stimulation for optimal cross-presentation which suggested that different 
stimulation conditions may have led to inconsistent results between different studies. These recent 
controversies between different studies questions as to whether CD141
+
 DC are the most superior 
cross-presenting DC subsets in human.  
Many of the comparative studies have focused on the cross-presenting capacity of each human DC 
subset which involves reactivation of Ag-specific memory CD8
+
 T cells.  Compared to the naïve T 
cells, memory T cells require less stringent requirements to be activated which is attributed to their 
ability to respond to low doses of Ags and their lower dependency on the costimulatory signals (95-
97). These factors may contribute to CD8
+ 
T cells being less dependent on the intrinsic ability of 
DC subsets for priming. Furthermore, naïve T cell activation is a critical step that needs to be 
considered when designing a novel vaccine. There are no studies to date that have directly 
compared human DC subsets and their capacity to activate naïve Ag-specific CD8
+
 T cells. 
Therefore this highlights the importance of using naïve T cells as the responders for antigen 
presentation to assess the priming capacity of human DC subsets. 
The standard assay to examine antigen presentation is by measuring the proliferative response of 
Ag-specific T cells based on flow cytometry (e.g CSFE proliferation assay)  and to measure 
particular cytokines produced by T cells (e.g IFNγ, TNFα) through ELISA or ELISPOT (74, 84, 93, 
98). The major limitation of proliferation assays is that they do not measure the activity of the 
proliferating T cells (99, 100), but has been shown to be correlate with clinical outcome of infection 
(101, 102). Furthermore, the drawback of using ELISA is that although it measures the total amount 
of cytokine produced it cannot quantify the frequency of cytokine producing T cells and the level of 
cytokine produced at a single cell level (100). ELISPOT assays have been used to measure the 
frequency of cytokine producing T cells, but cannot phenotype the cytokine secreting cells and 
measure the quantity of the cytokine produced (103). Polyfunctional T cells, defined as T cells 
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having multiple effector functions, are associated with protective immune response to infectious 
disease (104, 105) and vaccination (106, 107). The key effector functions of CD8
+
 T cells are the 
cytotoxic activity and the ability to produce effector cytokines (e.g IFNγ, TNFα, IL-2). The 
frequency of IFNγ producing CD8+ T cells has been widely used as a parameter to assess antigen 
presentation by DC. IFNγ plays a role in clearance of numerous pathogens (108, 109) and also 
promotes Th1 CD4
+
 T cell differentiation (110). However, the frequency of IFNγ producing CD8+ 
T cells in some studies was insufficient to evaluate the quality of vaccine induced immunity (111, 
112) and breadth of Ag-specific T cell response (113, 114).  TNFα is also capable of controlling 
intracellular pathogens and has synergistic effect with IFNγ to enhance killing of pathogens (115-
117).  IL-2 produced by CD8
+
 T cells have autocrine effect on their IFNγ production (118) but also 
important in differentiation and proliferation of other immune cells (119). The cytotoxic activity of 
CD8
+
 T cells can be monitored by the expression of  degranulation marker CD107a (120). A set of 
parameters which include IFNγ, TNFα, IL-2 and CD107a expression can be used to better 
characterise the Ag-specific CD8
+
 T cell response. Advances in flow cytometry allow extensive 
analysis of the T cell function at a single cell level. Using this technology, both the cytotoxic 
activity (CD107a) and cytokine production by CD8
+
 T cells (IFNγ, TNFα, and IL-2) can be 
measured simultaneously and enables identification of polyfunctional T cells. Therefore the multi-
parameter flow cytometric based assay used in this study will provide better assessment of the 
CD8
+
 T cell priming by human DC subsets.  
1.5 DC immunotherapy 
The key feature of DC is to initiate T cell immunity, and of particular interest is induction of 
cytotoxic CD8
+
 T cells, which are the main immune defence against cancer and also infectious 
diseases. For this reason, DC have attracted great attention as a potential target to develop a novel 
preventative and therapeutic vaccines. 
1.5.1 Ex vivo generation of DC 
The conventional approach of DC based vaccines is to isolate monocyte precursors from the patient 
to generate DC ex vivo (121-123). These DC are activated and loaded with tumour Ag in ex vivo 
and reinfused into the patient to initiate an anti-tumour response by stimulating both CD4
+
 and 
CD8
+
 T cells. This approach involves ex vivo manipulation of DC that does not mimic the native 
environment, resulting in poor DC migratory capacity in vivo, which is a crucial factor that will 
substantially affect the efficiency to induce a potent immune response (124). Other limitations 
including the requirement of the vaccine to be tailor made for each patient, high cost, labour 
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intensive ex vivo manipulations and that mostly monocyte-derived DC (MoDC) are used, mean that 
this approach may not be the ideal target for optimal T cell stimulation (121).  
1.5.2 In vivo DC targeting 
A more simplified therapeutic approach is by directly targeting Ag to DC in vivo, which could 
possibly overcome the limitations encountered when using the ex vivo approach. This direct 
approach will circumvent the laborious and expensive ex vivo manipulations and is now capable of 
activating specific DC subsets in their native environment (121, 125, 126). Ag-conjugated 
monoclonal antibodies, specific for surface receptors expressed on DC, are used to deliver the Ag to 
DC. Therefore in vivo targeting could be an alternative approach that will be more cost effective 
and ideal to develop an “off the shelf” vaccine. 
The ideal receptor for targeting Ag should be DC-specific, should facilitate Ag uptake and also 
should have immunomodulatory properties that favours CTL immunity. The most commonly used 
receptor for targeting studies is the CLR.  These receptors have endocytic properties and also 
promote Ag processing through both MHC Class I and MHC Class II pathways.  
The first and most extensively characterised CLR for Ag targeting is DEC205, which is 
predominantly expressed by DC subsets including the mouse CD8
+
 DC (127-129). In mouse studies, 
targeting Ag to DEC205 with maturation signals has shown to induce both CD4
+
 Th1 and CTL 
responses and also improved anti-tumour immunity in a melanoma model (130). In the absence of 
maturation signals, the response led to tolerance mediated by the activation of regulatory T cells 
(Treg) (131, 132). However, unlike the mouse, DEC205 is expressed in variety of cell types in the 
human including T cells, B cells, macrophages and natural killer (NK) cells (133). This raises a 
question as to whether antibodies targeting receptors that are also expressed on non-DC, will be 
more readily cleared or will not persist as long in vivo which could lead to off-target effects and 
reduced targeting efficiency to DC. Persistence of Ag presentation has been demonstrated to be 
crucial for driving an immunogenic T cell response (134) and also play a role in the development of 
follicular helper (Tfh) T cells that are associated with humoral immunity (135, 136). Despite being 
expressed by multiple cell types, targeting Ag to CD11c (137), CLEC12A (138) and CD36 (139) in 
mice has been successful in delivering Ag for presentation by both MHC Class I and MHC Class II 
molecules to prime T cells. Although the broad expression pattern of the receptors did not prevent 
induction of immune response, it was specifically the DC that were responsible for the T cell 
priming (138, 140). The first in human study was performed by targeting NY-ESO-1 Ag using 
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humanised Ab against DEC205 (CDX-1401) to treat multiple solid malignancies and have shown 
encouraging clinical results (141).  
CLEC9A is more restricted in its expression pattern, which is expressed on CD8
+
 DC and also 
weakly expressed on pDC in mouse (142) , but it is exclusively expressed on CD141
+ 
DC in 
humans (16, 143). Targeting Ag to CLEC9A in mice has led to the initiation of both Th1 and CTL 
responses (124, 136, 144). Using a melanoma model, targeting Ag to CLEC9A induced protective 
anti-tumour immunity (145). Our lab has constructed novel humanised Ab against these receptors 
that can be tested to target Ag to human DC. However testing the efficacy of these Ab in humans 
has been limited due to ethical restrictions and the paucity of human CD141
+
 DC (79). Therefore an 
in vivo model that accurately represents human immune system is urgently needed.  
1.5.3 Vaccine adjuvants  
TLR ligands are recognised as potent vaccine adjuvants due to their ability to activate DC and 
potentiate T cell mediated immunity. Of particular interest are the intracellular TLRs (TLR3, 
TLR7/8 and TLR9) as they have been considered effective targets for synthetic vaccine adjuvants 
(125). However what needs to be considered is that TLR expression profile is different between 
mouse and human DC that may limit the translation from mice to human studies. TLR9 is expressed 
on all mouse DC subsets (146, 147). Administration of CpG, a TLR9 ligand, has been demonstrated 
in clinical trials to boost humoral and cellular immunity (148). However in humans, TLR9 
expression is restricted to pDC and B cells (81, 125, 149) which suggests that CpG will be an 
effective adjuvant for vaccine targeting pDC but not for cDC. Although both mouse CD8
+
 DC and 
human CD141
+
 DC commonly express TLR3, human CD141
+
 DC lack the expression of TLR4 and 
9 that are expressed on mouse CD8
+
 DC (125). Since CD1c
+
 DC also express TLR3, the TLR3 
ligand, poly IC (synthetic dsRNA), could be an effective adjuvant to be used to activate both 
CD141
+
 DC and CD1c
+
 DC. Poly IC mediated DC activation led to enhanced MHC Class II 
presentation and cross-presentation that was associated with potent Th1 and CTL responses (77, 79, 
150). Poly IC also activate cytosolic receptor MDA5, that induce large systemic levels of IFNα 
produced from nonhaematopoietics cells (54, 151). IFNα enhance cross-presentation in DC and 
resulted in potent anti-tumour response and tumour rejection (152, 153). The synthetic stabilised 
analogue poly ICLC has been well tolerated in humans and is very effective in inducing type I IFN 
response and inflammatory cytokines (154). This shows that poly IC and the stable analogue poly 
ICLC are attractive candidate for vaccine adjuvant that focuses on inducing cell mediated immune 
responses. The TLR7/8 ligand, R848 (synthetic molecule), is also an attractive adjuvant as it is 
capable of activating multiple DC subsets in humans (150, 155). One study has compared the 
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effects of various TLR ligands on DC maturation in vivo and demonstrated that R848 was the only 
TLR ligand that was capable of activating all human DC subsets (150). Interestingly, R848 induced 
higher upregulation of maturation markers by pDC compared to CpG and also induced IFNα 
production with similar level to poly ICLC activated CD141
+
 DC.  
Many studies have performed functional analysis on DC activated by a single TLR ligand. It is well 
known that pathogens express several PAMPs and most likely will involve triggering multiple 
TLRs in distinct cellular compartments. There is strong evidence that TLR ligands can have a 
synergistic effect in activating DC with enhanced effector functions (156). Particularly the 
combination of poly IC and R848 has led to enhanced antigen presentation and Th1 mediated 
responses by human MoDC (157, 158).  However these studies were based on using MoDC that is 
widely used as a model for myeloid DC but does not accurately reflect the functional properties of 
different DC subsets (159, 160). Combined administration of TLR ligands (poly ICLC and R848) 
have also been demonstrated in clinical trials (141). In this study, there was no cases of major 
adverse effects and induced both cellular and humoral immunity against the cancer NY-ESO-1 Ag 
and in some patients tumour regression was observed. The clinical trial study demonstrate the safety 
and effectiveness of combined administration of poly ICLC and R848 that could be potential 
candidate for vaccine adjuvant. To date, there are no studies that have analysed the effect of TLR 
ligand combination on human DC subsets (CD141
+
 DC, CD1c
+
 DC and pDC). Directly comparing 
the role of TLR ligands on human DC subsets will provide better understanding in designing 
adjuvant for DC based vaccines. 
1.6 Humanised mouse model  
Functional characterisation of human DC subsets has been limited due to the low frequency of DC, 
especially CD141
+
 DC which constitutes only 0.03% of the PBMC (79) as well as accessibility and 
difficulty to isolate human DC subsets from apheresis products. In addition there is a lack of models 
to study basic human DC biology in vivo and for evaluating human vaccines. 
Humanised mouse models are now becoming the hot topic in immunology to serve as a platform for 
developing new vaccine strategies (161). Humanised mice are generated by using immunodeficient 
mice engrafted with CD34
+
 HSC, which leads to reconstitution of human immune cells and thus 
mimicking the human immune system. The commonly used humanised mouse was generated using 
NOD.CB17-Prkdcscid/J (NOD SCID) mice, which have impairment in the development and 
function of mouse T cells and B cells, and also reduced NK cell activity (162).  Haematopoietic 
engraftment was significantly augmented when NK cell blocking antibody was administered before 
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transplantation, suggesting that residual NK cell activity impedes CD34
+
 cell engraftment efficiency 
(163). Recent advances in genetic manipulation technologies have contributed significantly in 
generating the next generation immunodeficient strains to improve human haematopoietic 
engraftment in mice. Null mutation of IL-2 receptor gamma chain (IL2Rγ chain) was introduced in 
NOD SCID mice (NOD/SCID/IL2 receptor γ null mice; NSG mice) which disrupts the signalling of 
various cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) (164), leading to severe impairment in 
mouse NK cell activity and lack B and T cells  (165). NSG mice are one of the most 
immunodeficient mouse strains described to date. More importantly, the NSG mouse strain was 
most efficient in human CD34
+
 cell engraftment even with limited doses (166).  
The major limitation of using NOD SCID mice is that it cannot support the development of human 
T cells (167, 168). The use of NSG mice has significantly improved the development of functional 
human T cells that can be detected in high frequencies (169-171). However the lack of expression 
of human leukocyte antigen (HLA) molecules, the human MHC molecules, has resulted in the 
development T cells that cannot react to Ag in a HLA-restricted manner (172-174). To overcome 
this issue, transgenic NSG mice were generated to express the HLA A2.1 molecule (NSG-A2 mice), 
human MHC Class I, which permits development of human T cells with HLA A2-restricted 
function (172-174). This highlights the importance of having the expression of HLA A2 for the T 
cells to react against Ag in a similar manner to human T cells. The BM, liver, thymus (BLT) model 
is the most robust humanised mouse model to generate fully functional human T cells (175). BLT 
model are generated by cotransplanting fetal liver and thymus tissues along with autologous human 
haematopoietic fetal liver CD34
+
 cells (161).  However the use of this model is very limited due to 
ethical constraints to obtain fetal liver and thymus and technical difficulty involved in the 
transplantation of fetal tissues. Therefore in this project NSG-A2 mice have been used to generate 
the humanised mice.  
Our lab was the first to perform detailed analysis and demonstrated  that human DC subsets 
developed in the humanised NOD SCID mice was phenotypically and functionally similar to those 
found in human blood. Furthermore the administration of the growth factor, FLT3-L, led to 
expansion of human DC subsets developed in humanised NOD SCID mice (176). Although there is 
no direct comparison between different mouse strains and the development of human DC subsets, 
there are strong evidence that functional human DC subsets can be generated in different mouse 
strains (150, 177, 178).  However detailed phenotype and functional analysis of DC subsets in 
humanised NSG-A2 mouse model have not been characterised. 
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Current studies on human DC subsets have relied on the isolation of DC subsets from apheresis 
products which involves expensive purification methods and DC subsets are found in such low 
frequencies that functional characterisation is limited. The availability of the humanised mouse 
model has provided opportunity to study the function of human DC subsets in both in vitro and in 
vivo settings. Further validation in the function of human DC subsets in humanised mice would 
allow for more in-depth studies to have a better understanding of the role of human DC subsets in 
immunotherapy. There is still lack of knowledge on the differences on the CD8
+
 T cell priming 
capacity between human DC subsets, in particular the activation of naïve CD8
+
 T cells. The aim of 
this study is to optimise and validate a humanised mouse model so that it can be used to further 
understand the function of human DC and evaluate new targeting vaccines. This model will also 
enable us to investigate the effect of different TLR ligands on DC subsets in vitro and in vivo.  
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Chapter 2: Materials and methods 
2.1 Mice 
NOD.Cg-Prkdc
scid
 Il2rg
tm1Wjl
 Tg(HLA-A2.1)1Enge/SzJ (NSG-A2) mice were obtained from 
Jackson Laboratories (stock number 014570). All mice were bred and maintained in TRI BRF 
animal facility. All mice were treated in accordance with approval by the University of Queensland 
Animal Ethics Committee (324/13). 
2.2 Media 
Complete medium: RPMI1640 (Invitrogen), 10% heat-inactivated AB serum (Invitrogen), 100U/ml 
Penicillin and 100µg/ml streptomycin (Invitrogen), 2µM L-glutamine (Invitrogen), 1mM sodium 
pyruvate (Invitrogen), 10mM HEPES buffer (Invitrogen), 0.1mM Non-essential amino acids 
(Invitrogen) and 50µM 2-mercaptoethanol (Sigma).  
2.3 CD34
+
 cell isolation 
Cord bloods (CB) were obtained from the Queensland Cord Blood Bank after informed consent in 
accordance with approval from Mater Adult Hospital Humans Ethics Committee (HREC1586M). 
Mononuclear cells (MNC) were extracted from CB by Ficoll Paque (GE Healthcare) density 
centrifugation. MNC samples were enriched for CD34
+
 cells with anti-hCD34 microbeads 
(Miltenyi) and isolated by autoMACS pro separator. Purity was evaluated by flow cytometer 
staining the CD34
+
 positive fraction with anti-CD34 FITC and anti-CD45 PerCP. Average purity 
was 79%(±14%) and the average CD34
+
 cell yield was 1.44x10
6
(±0.79x10
6
). The CD34
-
 fraction 
was screened for the human HLA A2 serotype using an anti-HLA A2 FITC and also used as a 
source of naive T cells. All data were acquired on the LSR II (BD Bioscience) and analysed using 
FlowJo software (Tree star, version6). 
Cryopreservation solution (10% DMSO/90% human plasma) was prepared. The cells were washed 
and resuspended in the cryopreservation solution. The cell suspension was aliquoted into a 
cryogenic vial and transported to a -70°C freezer in a Mr Frosty freezing container. Twenty four hr 
later, the cryovials were transferred directly to liquid nitrogen for long term storage. 
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2.4 Generation of humanised mice 
The humanised mice were generated from neonatal and adult NSG-A2 mice. This study mainly 
focuses on establishing the humanised mouse model using neonatal mice as it have been shown to 
improve human engraftment compared to adult mice (169, 179-181). Humanised mice were 
generated from neonatal mice (2-5 day old) similar to previously described method (182). The 
neonatal mice received 100cGy total body irradiation using 137Cs-source irradiator, 4hr prior to 
CD34
+
 cell injection. After 4hr, various doses of CD34
+
 cells (2x10
4
, 5x10
4
, 1x10
5
,
 
2x10
5 
in 50µl 
HBSS) were administered intrahepatically in mice.  
Adult mice (10-12wks) were also used to generate humanised mice as previously described with 
minor modifications (176). The adult mice received 250cGy body irradiation using 137Cs-source 
irradiator. After 24hr, 2x10
5
 CD34
+
 cells (100µl HBSS) were administered retroorbitally in mice. 
Engraftment was tested using retro-orbital bleed at 10wks and 12wks after CD34
+
 cell injection for 
neonatal mice and 4 wks post injection for adult mice. Red blood cells (RBC) were lysed by adding 
twice the volume of BD FACS lysing solution (BD Bioscience) to the whole blood.  Cells were 
washed twice with PBS and stained with anti-mouse CD45 PerCP Cy5.5 and anti-human CD45 
APC Cy7. The absolute hCD45
+
 cell count per µl of peripheral blood was determined using BD 
Trucount beads. Cells were washed and resupended with 5000 Trucount beads before being 
acquired on a FACS Cyan flow cytometer (BD Biosciences) and analysed using FlowJo software 
(Tree star, version6). The formula used to calculate the absolute hCD45
+
 cell count per µl of 
peripheral blood is as follows:  
Number of hCD45
+
 cells in the gated population/ number of beads in the gated population x 
Number of beads added/ blood volume (µl) 
Once engraftment was confirmed, the DC numbers were expanded in vivo using FLT3-L according 
to the established protocol in the humanised NOD SCID mouse model (176).  Recombinant 
huFLT3-L (BioXcell, 50µg/100ml PBS) was administered subcutaneously at day 1 and day 4 after 
engraftment being confirmed. DC were harvested from mice on day 8 or 9.  
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2.5 Human cell isolation from humanised mice 
Engrafted mice, 12-16wks post injection, were euthanized using CO2. Peripheral blood was 
collected in heparin via cardiac puncture. Red blood cells were lysed using FACS Lyse (BD 
Biosciences). BM was harvested by flushing followed by crushing the femur and tibiae. BM was 
passed through 40µm cell strainer to obtain a single cell suspension. Cells were isolated from 
spleen, liver and lung by enzymatic digestion using DNase I/Collagenase IV (100µl 2500U/ml 
Collagenase IV (Worthington) and 30µl 10mg/ml DNase I (Roche)) for 30min at room temperature. 
Six hundred µl of 0.1M EDTA (AnalaR) was added for the last 5min of the digestion incubation. 
Dispersed cells were washed in complete media and passed through a 40µm cell strainer. MNC 
were isolated by density gradient centrifugation. Briefly, spleen and lung derived cells were 
resuspended in 1.077 Percoll (11ml Percoll (GE healthcare), 2ml of 1.5M NaCl (Sigma) and 7ml 
MilliQ water) and layered over a 1.077 Percoll.  Liver derived cells were resupended with 1.077 
Percoll and underlayed with 1.055 Percoll (1.87ml Percoll, 0.5ml of 1.5M NaCl and 2.63ml MilliQ 
water). Cell suspensions were centrifuged at 1400g for 15min at 4°C without braking. MNC 
obtained from BM, spleen, liver and lung were passed through 40µm cell strainer and resuspended 
in appropriate buffer.  
2.6 Analysis of human leukocytes in humanised mice 
Single cell suspensions of splenocytes, BM, liver, lung and peripheral blood from the engrafted 
mouse were labelled with mouse anti-human monoclonal antibodies, incubated on ice for 30min 
and then analysed using FACS Cyan flow cytometer (BD Biosciences). The following monoclonal 
antibodies were used for staining: anti-mouse CD45 PerCP Cy5.5, anti-CD45 APC Cy7, anti-CD3 
Pacific blue, anti-CD4 FITC, anti-CD8 PE Cy7, anti-CD19/20 Pacific blue, anti-CD14 APC, anti-
HLA DR PE Cy7, anti-CD123 PE, anti-CD1c FITC, and anti-CD141 APC. Dead cells were gated 
by staining with Live Dead® Aqua (Life Technologies). Flow cytometry data were analysed using 
Flow Jo software (Tree star, version 8). Absolute cell count of human cell subsets were determined 
by FACS using BD Trucount beads as mentioned above. The formula used to calculate the absolute 
cell count of human cell subsets is as follows: 
(Number of cells of particular subset in the gated population/ number of beads in the gated 
population) x Number of beads added x proportion of the organ (eg. If half of the organ used 
multiply by 2) or blood volume (µl) 
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2.7 DC isolation from humanised mice 
Single cell suspensions from BM (tibia, femur, pelvis and spine) of the engrafted mice were 
labelled with purified antibodies. The following purified monoclonal antibodies were used: anti-
CD3, anti-CD14, anti-CD19, anti-CD20, anti-CD34, anti-mouse CD45 and Ter119. Lineage 
depletion was performed using sheep anti-rat IgG Dynabeads (Invitrogen). After depletion, the 
samples were labelled with the following mouse anti-human monoclonal antibodies:  anti-CD45 
APC Cy7, anti-mouseCD45 PerCP Cy5.5, anti-CD19/20 Pacific blue, anti-HLA DR PE Cy7, anti-
CD123 PE or PerCP Cy5.5, anti-CD1c FITC, anti-CD141 APC. Dead cells were gated by staining 
with Live Dead® aqua (Life Technologies). DC isolation was performed by FAC sorting using 
Moflo Astrios (Beckman Coulter). 
2.8 Naïve T cell activation 
DC subsets were isolated from mice engrafted with HLA-A*02:01
+
 CD34
+
 cells. Each DC subset 
was pulsed with the HLA-A*02:01-restricted MART-1 ELA peptide (ELAGIGILTV, 50µg/ml) in 
the presence of activators (Poly IC- 10µg/ml (Invivogen), R848- 2µg/ml  (Invivogen)) for 2hr at 
37°C. Naïve CD8
+
 T cells from CB were purified by negative selection using CD8
+
 T cell isolation 
kit (Miltenyi) according to manufacturer’s protocol. Briefly, CB-derived MNC were stained with 
CD8
+
 T cell Biotin-Antibody Cocktail for 5min at 2-8°C. CD8
+
 T cell MicroBead Cocktail was 
added to the samples and incubated for additional 10min at 2-8°C. The samples were then loaded 
onto a magnetic column (Miltenyi, Column type: MS column) and the flow through containing the 
unlabeled cells, representing the enriched CD8
+
 T cells, were collected. The vast majority of cord 
blood-derived T cells are of naïve phenotype. HLA-A2-ELA specific naïve T cell precursors in cord 
blood have a naïve phenotype as shown by a study conducted by Neller et al (183). Peptide-pulsed 
DC were cocultured with naïve CD8
+
 T cells at a DC:T cell ratio of 1:10. At day3, 20U/ml IL-2 
(Hoffman-LaRoche) and 30% T cell growth factor (TCGF) (supernatant from Gibbon 
lymphosarcoma T cell line, MLA-144) were added to the cell culture. TCGF supports the growth of 
human T cells through Th1 cytokines including the constitutive expression of IL-2 (184, 185). At 
day21, the percentage of Ag-specific T cells and the quality of the T cells was measured. 
2.9 Pentamer staining 
The proportion of  CD8
+
 T cells that are specific against ELA peptide was assessed using APC 
labelled Pro5 pentamers (ProImmune). Briefly, T cells were stained with MelanA/MART 26-35 
APC labelled Pro5 pentamer for 20min in the dark at room temperature. After washing, the cells 
were stained with surface Ab (anti-CD3, anti-CD19, anti-CD14, anti-CD8 and Live Dead® aqua 
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(Life Technologies)) on ice for 15min. Samples were acquired on a LSR Fortessa flow cytometer 
(BD Biosciences) and analysed using Flow Jo software (Tree star, version 8). 
2.10 Polyfunctional assay 
The CB-derived CD8
+
 T cells were restimulated with 10µg/ml ELA peptide for 6hr, 37°C in the 
presence of brefeldin A (Biolegend), GolgiStop (BD Bioscience), anti-CD107a-FITC. Negative 
control without peptide was included. After stimulation, cells were washed with PBS and stained 
with surface marker antibodies (anti-CD4-BV711, anti-CD8-APC Cy7, Live dead® aqua (Life 
Technologies)). Cells were washed and permeablized according to the manufacturer’s protocol 
(Cytofix/Cytoperm; BD Biosciences). After washing with Perm/Wash™ buffer, the cells were 
stained with anti-TNFα-APC, anti-IFNγ-PE and anti-IL-2-Alexa700. The cells were subsequently 
washed with Perm/Wash™ buffer and fixed in PBS containing 1% paraformaldehyde. Samples 
were acquired on a LSR Fortessa cytometer (BD Biosciences) and analysed using Flow Jo software 
(Tree star, version 8). Boolean gating was performed using Flow Jo software (Tree star, version 8) 
to measure the frequency of each response based on all possible functional combinations of IFNγ, 
TNFα, IL-2 and CD107a. The Boolean gating provides every possible functional combination using 
AND and NOT Boolean logic for each cytokine. The proportion and composition (type of cytokines 
produced) of monofunctional (any one cytokine) and polyfunctional response (any two, three or 
four cytokines) can be determined using this analysis. This will provide detailed analysis of whether 
different DC subsets have any influence on the quality of T cell response (degree of 
polyfunctionality). No peptide control was used to subtract the background response for every 
functional combination. The data was analysed and graphed using Simplified Presentation of 
Incredibly Complex Evaluations (SPICE) software, version 5.3. 
2.11 DC stimulation with TLR ligands  
Engrafted mice were injected retroorbitally with poly IC (50µg, (Invivogen)), R848 (20µg, 
(Invivogen)) or the combination of poly IC and R848. Non-injected engrafted mice were used as a 
negative control. The serum was harvested at 2hr after treatment. The DC subsets were also isolated 
from the BM for RNA extraction and in vitro TLR activation. Freshly isolated DC were stained 
with either anti-CD80-FITC, anti-CD83-FITC, anti-CD86-FITC, anti-CD40-FITC, anti-CD70-
FITC or anti-IgG-FITC. The samples were acquired on a LSR Fortessa flow cytometer (BD 
Bioscience) and analysed using Flow Jo software (Tree star, version 8). Purified DC subsets from 
non-injected mice were resuspended with complete medium in a 96 well plate at a cell 
concentration of 5x10
4
/100µl. DC were stimulated in vitro with combination of 10µg/ml poly IC 
(Invivogen) and 2µg/ml R848 (Invivogen) for 18hr at 37°C. Complete medium alone was used as a 
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negative control. After 18hr of incubation, the supernatant was harvested to measure the cytokine 
and chemokine levels. Remaining cells were used to determine the expression of maturation 
markers as mentioned above. 
2.12 Cytokine and chemokine detection 
The cytokine (IL-1β, IL-6, IL-10, IL-12p70, IL-18, IL-23, IL-27, IFNα and TNFα) and chemokine 
(CCL5, CXCL9, CXCL10, CXCL11) levels in the serum and DC cultured supernatants were 
measured using LEGENDplex custom array (BioLegend) according to the manufacturer’s protocol. 
Briefly, samples (serum or supernatants) and standards were incubated with 12.5µl of assay buffer, 
12.5µl of cytokine/chemokine capture bead cocktail and 12.5µl of detection antibodies.  Matrix B 
(instead of assay buffer) was added to the standard wells for the serum. The plates were incubated 
for 2hr in the dark at room temperature on a plate shaker (approximate 600rpm). This was followed 
by the addition of streptavidin- PE and further incubated for 30min. Samples were washed in 200µl 
1x wash buffer, pellets were resuspended in 150µl 1x wash buffer and samples were acquired on 
FACS Canto (BD Bioscience). Data was analysed with the LEGENDplex software (Biolegend). 
The IFNλ level in the serum and DC cultured supernatants were measured using ELISA kit (IL-29, 
R&D systems). The absorbance at 450-570nm was measured using POLARstar Omega Microplate 
Reader (BMG Labtech) and data analysed using GraphPad prism software (version 6.0) 
2.13 Preparation of cRNA and microarray experiments 
Cell pellets of freshly isolated primary DC were dissolved in TRIzol Reagent (Life Technologies). 
After chloroform extraction, total RNA was precipitated in isopropanol, washed with 70% ethanol 
and resuspended in 14µl of ultrapure distilled water. The quantity and integrity of the RNA were 
measured using the Agilent 2100 Bioanalyzer RNA Nano chip (Agilent Technologies). Only RNA 
samples with RNA integrity numbers (RIN) > 8 were further processed. Total RNA (450ng) was 
converted to cDNA and subsequently into cRNA using Illumina TotalPrep RNA Amplification Kit 
(Ambion). A 14hr in vitro transcription was performed. The quantity of cRNA was measured using 
Trinean DropSense96 UV/VIS droplet reader. Amplified cRNA (750ng) for each sample was 
hybridised onto HumanHT-12 v4 Expression BeadChip Kit (Illumina) according to the 
manufacturer’s protocol. Two BeadChip  array carrying all 24 samples were scanned on an Illumina 
BeadArray Reader (Illumina). 
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2.13.1 Data processing 
Microarray data processing was performed by the Stemforamtics Team. Data was processed using 
the Illumina Beadstudio software (Genomestudio). Quality control of the microarray data was 
performed by observing any sample with unusually low number of detected transcripts in Illumina 
BeadStudio. One sample (3998755167_L _CD1c_Ctrl) had very low number of detected transcripts 
and therefore was removed from downstream analyses. This was due to low concentration of cRNA 
that could not be further concentrated to reach the recommended 150µg/µl cRNA concentration 
with total cRNA quantity of 750ng (Appendix 2). The microarray expression data were imported 
into the Lumi package (186) for further data processing. 
Additional quality control step was included to identify any obvious outliers by hierarchical 
clustering and boxplot generated by the Lumi package. The outliers were detected based on the  
poor linear ranges in the boxplot as well as the distance to the center of the cluster. Four samples 
(3998755170_A_CD141_PIC, 3998755167_B _CD141_R848,  3998755167_C _CD1c_PIC/R848 
and 3998755167_E _CD141_Ctrl) were identified as outliers and therefore were removed from 
downstream analyses (Appendix 3). Two samples (3998755167_B _CD141_R848 and 
3998755167_C _CD1c_PIC/R848) had low cRNA concentration than recommended (Appendix 2). 
The microarray data was background corrected followed by log2-transformed and quantile 
normalisation.  
Transcripts differentially expressed by CD141
+
 DC and CD1c
+
 DC, were identified using ANOVA 
analysis with p value cutoff threshold of 0.05 (after Bonferroni correction). Additionally, the 
microarray data was integrated into the stem cell collaboration platform (www.stemformatics.org). 
Microarray studies conducted by Haniffa et al. and Robbins et al. have identified list of genes that 
were differentially expressed between different human DC subsets (CD141
+
 DC and CD1c
+
 DC). 
These lists of differentially expressed genes were used to compare with the list of differentially 
expressed genes that were identified between CD141
+
 and CD1c
+
 DC purified from humanised 
mice. To observe the similarity and difference between the list of differentially expressed genes, we 
have generated the Venn diagram using Oliveros, J.C. (2007-2015) Venny. An interactive tool for 
comparing lists with Venn's diagrams. http://bioinfogp.cnb.csic.es/tools/venny/index.html. 
Differentially expressed genes were also uploaded to InnateDB. The pathway overrepresentation 
analysis was performed to determine which pathways were significantly overrepresented in the 
upregulated gene datasets for each DC subsets using the hypergeometric test. InnateDB 
simultaneously tests for overrepresentation of pathways from the KEGG (187), PID (188), INOH 
33 | P a g e  
 
(189), NetPath (190), and Reactome (191) databases. The Benjamini and Hochberg (BH) FDR 
correction was applied to correct for multiple testing (p<0.05). 
2.14 Statistical analysis 
Difference between two groups were tested using Mann-Whitney test for unpaired data or Wilcoxin 
signed-rank test for paired data. Comparison between more than two groups were performed using 
Kruskal-Wallis test. The level significance was set at p<0.05 and statistical tests were performed 
using GraphPad prism software (version 6.0).  
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Chapter 3: Development and characterisation of humanised NSG-A2 mice 
3.1 Introduction 
The development of a physiologically relevant model system that enables both in vitro and in vivo 
approaches to understand the functional and phenotypical characterisation of human cells is in high 
demand. This is especially evident in studies involving the characterisation of human dendritic cells 
due to their rarity, difficulty of access and the cost involved in isolating these cells. The generation 
of humanised mouse models through the transplantation of human CD34
+
 HSC into 
immunodeficient mouse strains has allowed reconstitution of human leukocytes to develop a mouse 
model bearing human immune system components. The use of humanised mice offers many 
opportunities as a relevant preclinical model to assess the immune response against human-specific 
infectious diseases and cancer.  
There are various parameters that could influence the efficiency of human cell engraftment. These 
include HSC injection route, age of mice and source of HSC. The 3 main injection routes for 
neonatal mice are intrahepatic(173, 192-194), intracardiac(195) and intravenous injection(169, 
172) . Among these, the intrahepatic injection route has been commonly used as it is technically 
more simple than other injection routes. Brehm et al. (179), have evaluated several parameters and 
concluded that intrahepatic injection of HSCs into neonatal mice resulted in best engraftment 
compared to adult mice. Neonatal mice were also shown to support better development of T cells 
compared to adult mice (179).  This could be due to human HSC being introduced before thymic 
dysplasia occur and possibly human cells contribute to thymic organogenesis. However the 
mechanism underlying the superior development of human cells in neonatal mice is unknown, 
Therefore neonatal mice are superior to adults as hosts for engraftment of human HSC. In terms of 
the HSC, the 3 main sources are from G-CSF-mobilised adult peripheral blood, CB and fetal liver. 
Lepus et.al (196) have directly compared these HSC sources using humanised mice and have 
demonstrated that CD34
+
 cells from human fetal liver and CB provided higher reconstitution level 
of hCD45
+
 cells and the breadth of developing various human immune cell types.  The ethical 
constraints and difficulty in obtaining fetal liver tissues makes them not feasible as a source of HSC.  
In addition, CB is more beneficial because it is easily accessible, enriched for HSC and there is no 
risk to the donor. However the cell dose of CD34
+
 cells required to achieve stable engraftment is 
not well characterised. The cell dose (10
4
-5x10
5
) used to develop humanised mice varies from lab to 
lab (173, 177, 194), which suggests that the cell dose was determined empirically by each study. It 
is not clear which cell dose would consistently achieve high reconstitution level of human cells. The 
time of engraftment is also important, since there is a consistent pattern showing early 
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differentiation of B cells (1-3months) and late T cell (3-5months) reconstitution (170, 171, 197, 
198). Identifying the optimal time of engraftment, where all human cell lineages can be detected, is 
absolutely critical to obtain consistent results. This is because the different cell composition 
between early and late time points could contribute to the changes in immune responses that may 
lead to misleading interpretation of the results. Finally, the cell composition, phenotype and 
function of human cell subsets developed in humanised mice needs to be validated as to whether it 
accurately reflects those found in human. Therefore this study involves determining optimal cell 
dose, time of engraftment, phenotype and proportion of human cell subsets that develop in the 
humanised NSG-A2 mice.  
3.2 Results 
3.2.1 Engraftment with CB-derived hCD34
+
 HSC in NSG-A2 mice 
To determine the optimal dose of CD34
+
 cells, the neonatal mice were injected intrahepatically with 
various doses of CB-derived CD34
+
 cells (2x10
4
, 5x10
4
, 1x10
5
, and 2x10
5
) and human chimerism 
was assessed in the peripheral blood at 10 wks post injection using flow cytometry (Fig. 3.1). 
Interestingly, there were 3 populations of cells (mCD45
+
 cells, hCD45
+
 cells and double negative 
cells) detected in the peripheral blood by flow cytometric analysis (Fig. 3.1). The proportion of 
these double negative cells (mCD45
-
 hCD45
-
 ) seems to vary between mice that may affect the 
percentage of hCD45
+
 cells (Table 3.1).  
 
Figure 3.1: Engraftment of human haematopoietic cells in NSG-A2 mice. Neonatal mice (1-5 
days old) were injected intrahepatically with CB-derived CD34
+
 HSC and engraftment was 
evaluated in peripheral blood at 10wks post injection. Representative gating strategy to identify 
human cells. The trucounts beads were gated by plotting FITC vs APC Cy7. Live cells were gated 
on forward scatter (FSC) and side scatter (SSC). There were 3 populations identified by plotting  
mCD45 vs hCD45, which human cells represent the mCD45
-
 hCD45
+
 population.  
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No. mCD45
-
 hCD45
-
 (%) mCD45
-
 hCD45
+
(%) 
7 70.3 17.2 
8 84 5.64 
9 77.1 15.1 
10 54.6 26.5 
11 55.5 8.86 
12 56.9 12.3 
13 32.5 26.8 
14 62 17.1 
Table 3.1: Proportions of double negative cells (mCD45
-
 hCD45
-
) and human cells (hCD45
+
) 
in peripheral blood of humanised NSG-A2 mice. Neonatal mice (1-5 days old) were injected 
intrahepatically with the same CB-derived CD34
+
 HSC and engraftment was evaluated in peripheral 
blood at 10wks post injection. 
 
Firstly, the engraftment level was calculated based on the percentage of hCD45
+
 cells in the 
peripheral blood. Mice with ≥5% hCD45+ cells in the peripheral blood were considered as 
engrafted. All cell doses achieved detectable engraftments level but the success rate decreased with 
titrating cell dose. One of 8 mice (25%) for 2x10
4
, 1 of 10 (25%) mice for 5x10
4
, 24 of 53 mice 
(45%) for 1x10
5
, 19 of 20 mice (95%) for 2x10
5
 showed ≥5% hCD45+ cells in the peripheral blood 
at 10 wks post injection (Fig. 3.2A).  
The trucount beads have been used to determine the absolute number of hCD45
+
 cells which will 
not be affected by the double negative population. Mice with 5-6% hCD45
+
 cells in peripheral 
blood had an average of 89 hCD45
+
 cells/ul blood. The threshold level was set to 90 hCD45
+
 
cells/ul peripheral blood, which would be classified as high engraftment and was used for 
subsequent experiments. Based on this strategy, the minimum dose that would achieve high 
engraftment level was 1x10
5
 CD34
+
cells in which 15 of 53 (28%) of the mice was above the 
threshold level (Fig. 3.2B). Thirteen of 20 (65%) of the mice injected with 2x10
5
 CD34
+
 cells were 
highly engrafted (Fig. 3.2B). Therefore the optimal dose of CD34
+
 cells that can consistently 
generate highly engrafted humanised mice was 2x10
5
.  
We have also investigated whether the engraftment level increases over time. Similarly we 
compared the percentage and absolute number of hCD45
+
 cells in peripheral blood at 10wks and 
37 | P a g e  
 
12wks post injection (Fig. 3.2C and D). However there was no improvement in the engraftment 
level from 10-12wks. To confirm if neonatal mice support better HSC engraftment than adult mice, 
we injected both neonatal and adult mice with the same number of CD34
+
 cells (2x10
5
) and 
compared the level of hCD45
+
 cells in peripheral blood. Similar to previous studies (169, 179-181), 
we also observed significant higher engraftment levels of hCD45
+
 cells in peripheral blood of 
neonatal mice compared to adult mice (Fig. 3.3). 
 
Figure 3.2: Increased engraftment in NSG-A2 mice with higher cell doses of human 
haematopoietic cells. Neonatal mice (1-5 days old) were injected intrahepatically with various 
doses of cord blood (CB) derived CD34
+
 HSC (2x10
4
, 5x10
4
, 1x10
5
 or 2x10
5
, x-axes).  (A) The 
percentage and (B) absolute cell count of hCD45
+
 cells in the peripheral blood was measured at 
10wks post injection. Dotted line indicates 5% hCD45
+
 cells and grey line indicates 90 hCD45
+
 
cells per ul blood.  Each symbol represents an individual mouse, and the bars indicates mean±SEM. 
*P < 0.05, **P < 0.01, *** P < 0.001 by Kruskal-Wallis test.  (C and D) Engraftment of human 
haematopoietic cells was determined over time. The percentage and absolute cell count of hCD45
+
 
cells in the peripheral blood was measured at 10wks and 12wks post injection. Each symbol 
represents an individual mouse.  
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Figure 3.3: HSC engraftment in neonatal and adult NSG-A2 mice. Neonatal mice (1-5 days old) 
and adult mice (10-12wks old) were injected with CB- derived CD34
+
 HSC (2x10
5
) as described in 
Materials and Methods.  The absolute cell count of hCD45
+
 cells in the peripheral blood was 
measured at 10wks post injection for neonatal mice and 4wks post injection for adult mice. Each 
symbol represents an individual mouse, and the bars indicates mean±SEM. **** P < 0.0001 by 
Mann-Whitney test.  
 
Previous studies have reported that female mice have higher levels of engraftment compared to 
male mice in the BM, spleen and thymus (199) and the human lineage distribution was found to be 
similar between the female and male recipient mice. In this study, we compared the percentage and 
the absolute number of hCD45
+
 cells in the peripheral blood between female and male recipients 
that have received same dose of CD34
+
 cells (2x10
5
). Interestingly, both genders had very similar 
engraftment level in the peripheral blood (Fig. 3.4A and B). However female mice had significantly 
higher engraftment level in the BM but were still only approximately 1.4 fold higher compared to 
male mice (Fig. 3.4C).  
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Figure 3.4: Gender difference in engraftment of human HSC. Male and female recipient mice 
were transplanted with CB-derived CD34
+
 HSC and engraftment was measured in peripheral blood. 
(A) The percentage and (B) absolute cell count of hCD45
+
 cells was measured at 10wks post 
injection. (C) The mice were injected with FLT3-L (50ug/ml) at day 1 and day 4 and the BM was 
harvested at day 8 or 9. The percentage of hCD45
+
 cells within the lineage depleted BM cells was 
determined. Each symbol represents an individual mouse, and the horizontal bar indicates 
mean±SEM. *P < 0.05 by Mann-Whitney test.   
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3.2.2 Robust multilineage differentiation of HSC in NSG-A2 mice 
Next we investigated whether the transplanted HSC have undergone multilineage differentiation 
and migrated to various lymphoid (BM and spleen), nonlympoid organs (liver and lung) and were 
present in peripheral blood. As shown in figure 3.5 and 3.6, multilineage cells were observed in 
BM, spleen, liver, lung and peripheral blood. These cells include CD14
+
 monocytes, CD19/20
+
 B 
cells, T cells (CD3
+
 CD4
+
 and CD3
+
 CD8
+
) and DC. Gating on the basis of HLA DR, CD19/20, 
CD141, CD1c and CD123 expression enabled us to distinguish between the 3 major human DC 
subsets (CD141
+
 DC, CD1c
+
 DC and CD123
+
 pDC) (Fig. 3.5).  Previous studies have reported that 
B cells also express CD1c and therefore the CD19/20 markers are required to identify the true 
population of CD1c
+
 DC(200). Therefore the phenotype of the DC subsets found in humanised 
NSG-A2 mice closely resembles DC subsets found in human (73, 79)  
 
Figure 3.5: Representative analysis of DC subsets and B cells in the BM, spleen, liver, lung 
and peripheral blood of humanised NSG-A2 mice. Trucount beads were gated by plotting FITC 
vs APC Cy7. Dead cells were excluded by staining with Live Dead Aqua. Human cells (hCD45
+
) 
were selected and gated according to the expression of HLA DR. HLA DR
+
 cells were gated and 
separated from B cells (CD19/20) to identify the DC subsets based on the expression of CD141
+
 
DC, CD1c
+
 DC and CD123
+
 pDC. Numbers represent the percentage of the parent gate. Data are 
representative of 5 independent experiments. 
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Figure 3.6: Representative analysis of monocytes and T cells in the BM, spleen, liver, lung and 
peripheral blood of humanised NSG-A2 mice. Trucount beads were gated by plotting FITC vs 
APC Cy7. Dead cells were excluded by using the Live Dead Aqua. Human cells (hCD45
+
) were 
selected and further gated for monocyte (CD14
+
) and T cells (CD3
+
). T cell subsets were 
distinguished according to the expression of CD4 and CD8. Numbers represent the percentage of 
the parent gate. Data are representative of 5 independent experiments 
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The percentage of hCD45
+
 cells in the spleen was higher compared to BM (tibia and femur) (Fig. 
3.7A).  Interestingly, however there was a higher percentage of hCD45
+
 cells in the liver compared 
to BM. The majority (>60%) of hCD45
+
 cells were CD19/20
+
 B cells in the BM, spleen and 
peripheral blood (Fig. 3.7B). The proportion of hCD45
+
 cells that were CD14
+
 monocytes was 
higher in the liver (9.6%) and lung (14%) compared to BM (3.9%), spleen (1.6%) and peripheral 
blood (5.8%) (Fig. 3.7B). Interestingly there was higher percentage of CD3
+
 T cells in the liver and 
lung compared to spleen. On average, the percentage of DC in the total hCD45
+
 population were 
5% in BM, 2% in spleen, 16% in liver, 9% in lung and 4% in peripheral blood (Fig. 3.7B). CD1c
+
 
DC was the dominant cDC subset found in the BM, spleen, liver and lung, whereas in the peripheral 
blood CD141
+
 DC predominated.  Furthermore, there was higher proportion of pDC compared to 
CD1c
+
 DC or CD141
+
 DC in the BM, spleen and peripheral blood. However in the liver and lung, 
there was a higher percentage of CD1c
+
 DC than pDC.  
The absolute number of each cell subset was calculated using the trucount beads. Overall the BM 
had the highest cell count for all cell types, with the exception of T cells which were found most in 
the spleen (Fig. 3.7C). BM has been reported previously to be the major reservoir for human 
dendritic cells in humanised mice (176). Similarly, BM displayed the highest frequency of human 
DC subsets, whereas there was very low frequency of human DC subsets in the lung and peripheral 
blood (Fig 3.7C). Therefore DC subsets used for subsequent experiments were purified from BM.   
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Figure 3.7: NSG-A2 mice support robust multilineage differentiation of HSC in lymphoid and 
nonlymphoid organs. Multilineage differentiation of HSC was determined in the BM (single tibia 
and femur), spleen, liver, lung and peripheral blood (1ml) at 13-14wks post injection of cord blood 
derived CD34
+
 HSC (n=5-8 mice). (A) Percentage of hCD45
+
 cells among the total MNC. (B) 
Percentage of each cell types among the total hCD45
+
 cells. (C) Absolute cell count of each cell 
types was determined by Trucount beads. 
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3.3 Discussion 
There are many parameters that need to be considered when generating humanised mice. The 
injection route, age of mice and source of HSC have been well characterised (179, 196). 
Determining the cell dose required to achieve optimal engraftment is very critical especially 
because the number of CD34
+
 cells will be a major limiting factor due to restricted access to CB. As 
expected, the engraftment level increased with the increased cell dose injected into these mice. It is 
important to consider the fine balance of how many mice can be injected and how many mice will 
be engrafted well enough to be used for experiments. Our study has demonstrated that 2x10
5
 CD34
+
 
cells was the optimal cell dose that will achieve high engraftment level with high consistency. The 
average percentage of hCD45
+
 cells in peripheral blood was 16.5%, which was similar to previous 
studies (165, 181, 201), however other studies that had a much higher percentage of hCD45
+
 cells 
after engraftment (169, 192). This variation could be due to the difference in the purity of CD34
+
 
cells. The average purity of CD34
+
 cells used in this study was 80%, whereas other studies have 
only used CD34
+
 cells with purity ≥90% (170). CD38 is a stem cell lineage marker that is expressed 
on differentiated progenitor cells that has lost the repopulating capacity (202). These “true” 
repopulating  HSC defined as CD34+ CD38- cells have demonstrated successful engraftment of 
human cells in mice that required much less cell dose as compared to unfractionated CD34+ cells 
(169).  The lower purity of CD34
+
 cells in this study may have lower proportion of these highly 
primitive  HSC population (CD34+ CD38-), which might also account for the reduced engraftment 
level.  
The gender difference in the engraftment level has been reported from previous studies (199). We 
have observed minor increased engraftment level of female recipients compared to male recipients. 
Notta et. al(199) have also demonstrated that the striking difference in engraftment level between 
gender is only observed when transplanted with small doses of human HSC but the difference is 
largely disappeared with larger doses of human HSC. They have postulated that sex hormones 
could play a role in the advantage observed on female recipients but further clarification is required. 
In addition, whether the function of the human cells engrafted will be influenced by the gender of 
the recipient also needs to be elucidated. Nevertheless, both male and female mice can be used to 
generate humanised mice with no major influence in the engraftment level. In particular for the 
neonatal mice, it is very difficult to identify their sex at the time of engraftment (1-5 days after 
birth) and also the chance of having female pups is unpredictable, so being able to use both genders 
to generate humanised mice would be more beneficial. 
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The proportion of each cell subset found in humanised mice was very different to human. Most 
notably, B cells (CD19/20
+
) were present in high proportion (60% of hCD45
+
 cells) in the BM, 
spleen and blood.  Similar to previous studies, there was a consistent pattern observed in these 
locations whereby B cells represent the majority of hCD45
+
 cells, followed by T cells and then 
monocytes (166, 169, 177). However in human peripheral blood, the proportion of B cells is much 
lower than T cells and monocytes (203, 204). This suggests that in this model there is a bias 
towards the development of B cells. Furthermore, the percentage of each DC subset (CD141
+
 DC, 
CD1c
+
 DC and CD123
+
 pDC) in the BM and blood of humanised mice was greater than that in 
humans (79, 85, 204). This further highlights that the mouse microenvironment is not optimal for 
the development of particular human cell subsets and therefore this may have contributed to the 
difference in the cell composition compared to what is observed in human. There are other models 
that have been generated to improve the development and reconstitution of human cells. The NSG-
BLT model involves implanting human fetal thymic and liver tissues, which have demonstrated to 
facilitate in the development of T cells (205). Recently a new immunodeficient mouse strain, 
referred to as MISTRG mice, has been generated that has incorporated 4 different human cytokines 
(TPO, IL-3, GM-CSF and M-CSF) (178). These human cytokines facilitated in innate immune cell 
development to generate innate immune cells that more closely resemble those in humans. This 
shows that the current humanised mouse model does not have the optimal microenvironment for the 
development of human cells and there is still improvement required to accurately resemble the 
human immune system.  
Interestingly, the engraftment level was variable depending on tissue sample. While peripheral 
blood is easily accessible and convenient for evaluating engraftment level, this does not accurately 
predict the engraftment level in various lymphoid and non-lymphoid organs. Generally the 
engraftment level in the BM, spleen and liver is 2-4 fold higher than that in the peripheral blood. 
Most studies using humanised mice mainly focus on lymphoid and non-lymphoid organs to 
characterise human cells due to their paucity in the peripheral blood which limit functional studies 
to be conducted. BM can also function as secondary lymphoid organ as there are several studies 
showing that BM is a major reservoir of memory T cells and myeloid immune cells, which is 
considered as a lymphoid organ in addition to its more established role in haematopoiesis (206, 
207). Furthermore, BM-resident DC and circulating DC can prime Ag-specific T cells in the BM to 
induce primary and memory T cell response (208, 209). Recently, an immediate DC precursor (pre-
cDC) has been identified that are capable of differentiating into either CD141
+
 DC or CD1c
+
 DC 
(210). Pre-cDC were identified from the population that do not express CD141 and CD1c. Since 
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these BM-derived DC have been isolated based on the surface expression of CD1c or CD141, this 
further validates that these DC have already terminally differentiated into different DC subsets 
(CD141
+
 DC and CD1c
+
 DC) and are not DC precursors. 
In summary, we have characterised the potential of NSG-A2 mice to support human HSC 
engraftment and robust multilineage differentiation. The optimal CD34
+
 cell dose was identified 
which consistently achieves high engraftment in NSG-A2 mice. Human B cells, T cells, monocytes 
and DC subsets (CD141
+
 DC, CD1c
+
 DC and pDC) have reconstituted in the BM, spleen, liver, 
lung and peripheral blood. The phenotype of each cell subset identified in humanised mice was 
similar to those found in humans, however the cell composition was very different. This suggests 
that there is still further improvement necessary to accurately resemble the human immune system 
in the humanised mouse model. Therefore these data suggest that humanised NSG-A2 mice will be 
a robust model which provides the opportunity to investigate functional and phenotypical aspects of 
various human cell types in both in vitro and in vivo settings.   
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Chapter 4: Functional characterisation of human DC subsets in response to TLR stimulation 
in vivo  
4.1 Introduction 
DC based immunotherapy is an emerging therapeutic approach for treating against tumours and 
infectious diseases that relies on the ability of DC to stimulate T cells (211). Evaluating the 
immunoactivation potential of human DC has been limited due to their paucity and lack of models 
to characterise their function.  Humanised mouse model is a powerful tool to dissect the functional 
role of human DC subsets in vivo and further understand the interplay between different DC subsets. 
DC isolated from the humanised NOD SCID mouse model were shown to be phenotypically and 
functionally similar to the human blood counterparts in vitro (176). However detailed phenotype 
and functional analysis of DC subsets in humanised NSG-A2 mouse model have not been 
characterised. The validation of DC subsets developed in humanised NSG-A2 mouse model to 
closely resemble their human counterpart is essential to allow direct translation of knowledge 
gained from humanised NSG-A2 mice into humans. Comparative transcriptional analysis has 
demonstrated that homologies exist between mouse and human DC (75, 78). Numerous studies 
have identified genetic signatures that define each human subset (76, 85, 159, 212, 213). Using a 
similar approach, transcriptional analysis of DC subsets (CD141
+
 DC and CD1c
+
 DC) from 
humanised mice was performed to confirm whether they closely resemble to human blood DC 
subsets. 
DC based immunotherapy require potent adjuvants to induce DC maturation for enhancing T cell 
mediated immunity (214). TLR ligands have been used as vaccine adjuvants,  as they are potent DC 
activator (215). TLR ligands induce upregulation of costimulatory molecules (e.g. CD80, CD83, 
and CD86) that can be measured to monitor the activation level of DC and determine whether the 
DC are in the immature or mature state. DC are also capable of producing cytokines and 
chemokines in response to TLR stimulation that can mediate activation and differentiation of other 
cell types (8). TLR3 and TLR7/8 ligand (poly ICLC and R848) have been tested in clinical trials as 
a potential single or combinational cancer vaccine adjuvant (141, 155, 216). The combination of 
poly IC and R848 have also been reported to induce synergistic effect with enhanced IL-12p70 
production by CD1c
+ 
DC (158, 217), but this was not observed for CD141
+
 DC (83). The same 
TLR combination also enhanced cross-presentation by CD141
+
 DC (83). However whether other 
cytokines and chemokine also induced in synergy with poly IC and R848 on human DC has not 
been characterised. Furthermore, the effects of bystander/cross talk by other DC subsets and their 
activation in vivo has not been examined. Humanised mouse model will be useful to investigate 
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how human DC subsets respond to TLR ligands in vivo and evaluate whether the TLR combination 
will be a more powerful adjuvant than using a single TLR ligand. Therefore we compared the in 
vivo response of DC subsets from humanised mice to poly IC, R848 and the combination. 
4.2 Results 
4.2.1 Isolation of human DC subsets from humanised NSG-A2 mice  
Ding et al. (176) have developed a humanised mouse model with an enhanced number of human 
DC by injecting with the growth factor FLT3-L. The same study has also established a procedure to 
isolate human DC subsets from the BM of humanised mice. Similar to their study, DC subsets were 
identified and sorted in FLT3-L injected humanised NSG-A2 mice using the gating strategy as 
shown in figure 4.1A. The average yield of each DC subset from BM (tibia, femur, pelvis and 
spine) are as follows: CD141
+
 DC: 5.2x10
5
 CD1c
+
 DC: 9.52x10
5
 and CD123
+
 pDC: 8.58x10
5
 (Fig. 
4.1B). 
 
Figure 4.1: Sorting strategy for DC subsets and sorting yields. BM was isolated from FLT3-L 
injected humanised mice. DC subsets were sorted from lineage (mCD45, CD34, CD3, CD14, CD19, 
CD20) depleted BM. (A) Dead cells were excluded by staining with Live Dead Aqua. DC were 
gated as hCD45
+
HLA DR
+
Lin
-
 (CD3, CD14, CD19, and CD20) cells. DC subsets were sorted based 
on expression of CD141, CD1c and CD123. (B) Sorting yield for each DC subsets. 
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4.2.2 Validation of phenotypic markers by transcriptional analysis 
RNA from each purified CD141
+
 DC and CD1c
+
 DC samples from the BM of humanised NSG-A2 
mice were processed and hybridized to Illumina Human HT-12 v4 Expression arrays, which contain 
probe sets to identify more than 47000 transcripts. We firstly validated if the sorted DC subsets 
used in this microarray expressed the expected phenotypic markers by assessing the intensity 
signals for selected markers. CD141 (BDCA3), CD1c (BDCA1), HLA DRA, HLA DRB and the 
myeloid marker CD11c were used as positive control markers (Fig. 4.2A). As expected, CD141
+
 
DC and CD1c
+
 DC expressed CD11c, HLA DRA and HLA DRB, which confirms they are myeloid 
DC subsets. There was high expression of CD141 expression on CD141
+
 DC but below the 
detection level for CD1c
+
 DC. CD1c expression was also found to be expressed on CD141
+
 DC but 
was lower than CD1c
+
 DC. This was expected as FLT3-L treatment induces CD1c upregulation on 
CD141
+
 DC (176, 210, 218). To confirm that there were no contaminating cell types in the sorted 
DC subsets, we analysed the intensity signals of selected T cell (CD3), B cell (CD19), monocyte 
(CD14) and pDC (CD123) marker genes (Fig. 4.2B).  The expression of CD3 and CD14 were 
absent and CD19 and CD123 were detected at very low levels. Therefore the high expression of the 
expected phenotypic marker genes and low or absent of lineage CD marker genes, demonstrate that 
the isolation of CD141
+
 DC and CD1c
+
 DC were performed without contamination of other cell 
types.  
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Figure 4.2: Gene expression level of selected phenotypic markers. (A) Expression level of 
positive control marker genes, CD141/BDCA3, CD1c/BDCA1, CD11c, HLA DRA and HLA DRB. 
Y-axis represents the raw signal intensity. The mean±SEM from duplicates of each DC subsets are 
represented. (B) Expression levels of selected T cell (CD3), B cell (CD19), monocyte (CD14) and 
pDC (CD123) marker genes to determine any contaminating cell types. The mean values from 
duplicates of each DC subsets are represented. The values represent the signal intensity. The minus 
(-) sign denotes absence of expression of the selected markers that was below the detection 
threshold level. 
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4.2.3 Differential gene expression profiles by CD141
+
 DC and CD1c
+
 DC from humanised 
NSG-A2 mice 
We have identified list of statistically significant genes that were differentially expressed between 
CD141
+
 DC and CD1c
+
 DC using one-way ANOVA (p < 0.05). We found 277 and 203 
differentially expressed genes that were highly expressed on CD141
+
 DC and CD1c
+
 DC, 
respectively. We then further confirmed if these identified highly expressed genes were also found 
to be expressed by their human counterpart. There are several studies that have also performed 
transcriptome analysis and identified list of genes that were upregulated by human CD141
+
 DC and 
CD1c
+
 DC, respectively (75, 85). A Venn diagram was used to determine the overlap and difference 
between upregulated genes identified on each DC subsets from humanised mice with previously 
identified upregulated genes on their human counterpart (Fig. 4.3A). We observed more overlap of 
differentially expressed genes on CD141
+
 DC (70 genes) compared to CD1c
+
 DC (25 genes) with 
their human counterpart (Fig. 4.3A, Appendix 2) (75, 85). The 8 core genes expressed on CD141
+
 
DC that overlapped in all 3 studies were SEPT3, CLNK, FKBP1B, LRRC1, SNX22, GCSAM, 
CADM1/NECL2 and BTLA. Majority of these conserved core genes have unknown function, with 
the exceptions of cell adhesion molecule CADM1/NECL2 (219) and co-inhibitory molecule BTLA 
(220, 221). We have identified several core transcriptional factors and surface molecules highly 
expressed on CD141
+
 DC (IRF8, BATF3, ID2) and CD1c
+
 DC (IRF4, SIRPα and ITGAM /CD11b) 
(Fig. 4.3B). We also identified significantly differentially expressed genes in functional receptors 
between DC subsets (Fig. 4.3C). There were several CLR genes that were highly expressed on 
CD141
+
 DC (CLEC1A, CLEC7A, CLEC14A and CLEC9A) or CD1c
+
 DC (CLEC4A, CLEC10A, 
CLEC13A/CD302). The chemokine receptor, CXCR3 was highly expressed on CD141
+
 DC 
whereas CD1c
+
 DC highly expressed CCR2 and CX3CR1 as well as cytokine receptor IL13RA1. 
Surprisingly, the chemokine receptor XCR1 was undetectable on CD141
+
 DC, which has been 
previously described to be exclusively expressed on human CD141
+
 DC (74, 85, 213). In addition, 
DEC205 was also undetectable on either DC subset, which is well characterised to be abundantly 
expressed on these DC subsets (133, 222, 223). Interestingly TLR7 was the only TLR receptor that 
was significantly differentially expressed between DC subsets, which found to be highly expressed 
on CD1c
+
 DC. We then further compared the gene expression profile of TLR and RIG-I-like 
receptor (RLR) between DC subsets (Table 4.1). TLR1, TLR6, TLR7, TLR8, TLR10 was expressed 
on both DC subsets. TLR9 was undetectable on either DC subset. CD141
+
 DC expressed TLR3 that 
was not detected in CD1c
+
 DC. In contrast, CD1c
+
 DC expressed TLR4 and TLR5 that was not 
expressed on CD141
+
 DC. Among the RLR, CD141
+
 DC expressed MDA5 and LGP2 but the 
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expression of RIG-1 could not be detected (Table 4.1). In contrast, CD1c
+
 DC expressed all three 
RLR (Rig-1, MDA5 and LGP2). 
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Figure 4.3: Expression of conserved gene signatures of the DC lineage from BM-derived DC. 
CD141
+
 DC and CD1c
+
 DC were sorted from the BM of humanised NSG-A2 mice and processed 
for microarrays. (A) Venn diagrams showing the number of genes significantly upregulated in each 
DC subsets, as well as the overlap with previously identified list of upregulated genes on human 
CD141
+
 DC and CD1c
+
 DC (75, 85) (B) A heat map showing expression pattern of core 
transcriptional factors and surface molecules that were significantly differentially expressed on DC 
subsets from humanised mice. (C) A heat map showing expression pattern of functional receptor 
genes that were significantly differentially expressed between DC subsets from humanised mice. 
Colour represents high (red) and low (blue) expression intensity. Hierarchical clustering of genes 
were determined by Pearson correlation. 
 
Genes CD141
+
 DC CD1c
+
 DC 
Toll-like receptor 
TLR1 108.64 199.77 
TLR3 91.86 - 
TLR4 - 21.49 
TLR5 - 69.98 
TLR6 108.64 199.77 
TLR7 33.29 159.51 
TLR8 265.19 341.84 
TLR9 - - 
TLR10 480.71 1096.45 
RIG-I-like receptor 
RIG-1 - 33.59 
MDA5 333.88 324.29 
LGP2 133.06 123.88 
Table 4.1: Gene expression profile of TLR and RLR on DC subsets isolated from the BM of 
humanised NSG-A2 mice. Expression levels of TLR and RLR genes expressed on CD141
+
 DC 
and CD1c
+
 DC. The mean values from duplicates of each DC subsets are represented. The values 
represent the signal intensity. The minus (-) sign denotes absence of expression of the selected 
markers that was below the detection threshold level. 
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4.2.4 Over-represented pathways detected within the differentially expressed genes between 
CD141
+
 DC and CD1c
+
 DC 
The list of differentially expressed genes that were highly expressed on CD141
+
 DC or CD1c
+
 DC 
was submitted to the InnateDB pathway over-representation analysis tool (224). This determines 
which pathways were statistically over-represented in a given gene lists than expected by chance. 
Pathways that were significantly over-represented after correction with multiple testing (p ≤ 0.05) in 
CD141
+
 DC included the Erk and pi-3 kinase are necessary for collagen binding in corneal epithelia, 
nicotinate and nicotinamide metabolism, Mcalpain and friends in cell motility and signaling events 
mediated by focal adhesion kinase (Table 4.2). In contrast there were many significantly enriched 
pathways in CD1c
+
 DC and some of these included Signal regulatory protein (SIRP) family 
interactions, The NLRP3 inflammasome, Eicosanoid metabolism, Proximal tubule bicarbonate 
reclamation, Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell, 
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways, Fc 
epsilon receptor I signaling in mast cells (Table 4.3). Notably, CD1c
+
 DC upregulated several genes 
(CARD9, CASP1, CASP4, NLRP3 and NOD2) associated with NLR signalling pathway and 
inflammasome, which suggest these cells may play a role in NLRP3 inflammasome activity. 
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Pathway Name 
Pathway p-
value 
Proportion 
(%) 
Proportion 
gene list 
(%) 
Gene symbol 
Erk and pi-3 
kinase are 
necessary for 
collagen binding 
in corneal 
epithelia 0.007466293 16 1.87 
ACTN1; ITGB1; 
MAPK1; MYLK; 
PTK2; 
Signaling events 
mediated by focal 
adhesion kinase 0.013919696 14 1.49 
CD38; ENPP1; 
ENPP3; QPRT; 
Nicotinate and 
nicotinamide 
metabolism 0.038068221 13 1.49 
ITGB1; MAPK1; 
MYLK; PTK2; 
Mcalpain and 
friends in cell 
motility 0.039979859 12 2.24 
ACTN1; ASAP1; 
CCND1; ITGB1; 
MAPK1; PTK2; 
Table 4.2: List of significantly over-represented pathways that were detected from the 
differentially expressed genes highly expressed on CD141
+
 DC. Pathways were identified with 
InnateDB. Proportion represents the % coverage of the total genes that is associated with the 
pathway. Proportion gene list represents the % coverage of the total differentially expressed genes 
identified for CD141
+
 DC. Pathway p-value was corrected using Benjamini-Hochberg multiple 
testing. 
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Pathway Name 
Pathway p-
value 
Proportion 
(%) 
Proportion 
gene list (%) 
Gene symbol 
Signal regulatory protein 
(SIRP) family interactions 4.82E-04 29 2.25 
FYB; PTK2B; 
SIRPA; TYROBP; 
Immunoregulatory 
interactions between a 
Lymphoid and a non-
Lymphoid cell 5.41E-04 10 3.95 
AMICA1; 
FCGR2B; HCST; 
LILRB2; LILRB3; 
LILRB4; TYROBP; 
Eicosanoid metabolism 0.003455857 17 2.25 
ALOX5; 
ALOX5AP; 
CYSLTR1; PTGS1; 
Nucleotide-binding domain, 
leucine rich repeat containing 
receptor (NLR) signaling 
pathways 0.005088711 10 2.82 
CARD9; CASP1; 
CASP4; NLRP3; 
NOD2; 
Proximal tubule bicarbonate 
reclamation 0.026400876 13 3.95 
ATP1B1; CA2; 
PCK2; 
Fc epsilon receptor I 
signaling in mast cells 0.037304709 10 2.25 
BTK; FCER1A; 
PRKCB; 
The NLRP3 inflammasome 0.048690695 18 2.82 CASP1; NLRP3; 
Table 4.3: List of significantly over-represented pathways that were detected from the 
differentially expressed genes highly expressed on CD1c
+
 DC. Pathways were identified with 
InnateDB. Proportion represents the % coverage of the total genes that is associated with the 
pathway. Proportion gene list represents the % coverage of the total differentially expressed genes 
identified for CD1c
+
 DC. Pathway p-value was corrected using Benjamini-Hochberg multiple 
testing. 
 
 
 
58 | P a g e  
 
4.2.5 TLR and cytokine signalling pathways were over-represented within the differentially 
expressed genes in response to poly IC and R848 in vivo 
The TLR3 ligand poly IC and TLR7/8 ligand R848 have been used as potent adjuvant in vaccines. 
Longhi et al. (151) have demonstrated that cytokines were detected in the serum as early as 1hr post 
injection with poly IC, poly ICLC and R848 into mice. Based on this observation, we selected a 2hr 
timepoint for studies to investigate the effect of TLR ligands on human DC in vivo. Humanised 
mice were injected with poly IC, R848 or the combination and 2h later the DC subsets were isolated 
to perform microarray and also to characterise their phenotype by flow cytometry. We have 
identified 408 significant genes that were differentially expressed in response to the TLR treatments 
(poly IC, R848 or the combination) by DC subsets. We performed pathway over-representation 
analysis on these differential expressed genes to determine if the TLR treatment induced 
upregulation of genes that are associated with TLR signalling and cytokine signalling pathways. 
Notably, we have identified TLR or signalling pathway, canonical NF-kappaB pathway, as well as 
cytokine signalling pathways including interferon alpha/beta/gamma signalling, TNFalpha 
signalling and IL-1 signalling to be significantly over-represented (p ≤ 0.05) (Table 4.4). This 
demonstrates that poly IC and R848 can modulate genes associated with TLR and cytokine 
signalling pathways on both CD141
+
 DC and CD1c
+
 DC in vivo. 
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Pathway Name 
Pathway 
p-value 
Proportion 
(%) 
Proportion 
gene list (%) 
Gene symbol 
Interferon 
alpha/beta 
signaling 8.98E-14 31 4.41 
IFI6; IFIT1; IFIT2; IFITM1; 
IFITM2; IFITM3; IRF1; IRF7; 
IRF8; IRF9; ISG15; ISG20; 
MX1; MX2; OAS1; OAS2; 
OAS3; OASL; 
Interferon 
gamma 
signaling 5.53E-09 22 3.43 
CD44; GBP1; GBP4; ICAM1; 
IRF1; IRF7; IRF8; IRF9; OAS1; 
OAS2; OAS3; OASL; PML; 
SP100; 
TNFalpha 1.28E-08 10 6.37 
BAG4; BIRC3; CASP2; 
CASP7; FKBP5; MAP3K8; 
NFKBIA; NFKBIB; NFKBIE; 
NFKBIZ; NKIRAS1; NR2C2; 
PIK3R1; PML; POLR1C; 
POLR1D; PSMD12; TANK; 
TIFA; TNF; TNFAIP3; 
TNFRSF1B; TRAF1; TXN; 
UBE2I; USP11; 
Tnfr2 signaling 
pathway 6.77E-06 50 1.47 
LTA; NFKBIA; TANK; 
TNFAIP3; TNFRSF1B; TRAF1; 
RIG-I/MDA5 
mediated 
induction of 
IFN-alpha/beta 
pathways 4.86E-05 14 2.69 
DHX58; HERC5; IFIH1; IRF1; 
IRF7; ISG15; NFKBIA; 
NFKBIB; PCBP2; TANK; 
TNFAIP3; 
TNF receptor 
signaling 
pathway 5.01E-05 22 1.96 
BAG4; BIRC3; MAP2K3; TNF; 
TNFAIP3; TNFRSF1B; TRAF1; 
TXN; 
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RIG-I-like 
receptor 
signaling 
pathway 8.32E-04 13 2.2 
CXCL10; DHX58; IFIH1; IRF7; 
ISG15; NFKBIA; NFKBIB; 
TANK; TNF; 
Tnfr1 signaling 
pathway 9.05E-04 29 1.22 
BAG4; BIRC3; CASP2; 
LMNB1; TNF; 
Canonical NF-
kappaB pathway 0.027351 17 0.98 
NFKBIA; RIPK2; TNF; 
TNFAIP3; 
IL-1 signaling 
pathway 0.030128 13 1.22 
IL1B; MAP2K3; NFKBIA; 
NFKBIB; NFKBIE; 
Toll-like 
receptor 
signaling 
pathway 0.031169 8 1.96 
CXCL10; IL1B; IRF7; 
MAP2K3; MAP3K8; NFKBIA; 
PIK3R1; TNF; 
Table 4.4: Significantly over-represented pathways associated with TLR and cytokine 
signalling that were detected from the differentially expressed genes in DC stimulated with 
poly IC, R848 and the combination in vivo. Pathway that were identified with InnateDB. 
Proportion represents the % coverage of the total genes that is associated with the pathway. 
Proportion gene list represents the % coverage of the total differentially expressed genes identified 
in DC after TLR treatments (poly IC, R848 or the combination). Pathway p-value was corrected 
using Benjamini-Hochberg multiple testing. 
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4.2.6 Human DC upregulated costimulatory molecule genes in response to poly IC and R848 
in vivo 
We assessed the capacity of poly IC and R848 to induce maturation of DC after the 2h TLR 
stimulation in vivo. We compared the gene expression profile of the costimulatory and co-inhibitory 
molecules on CD141
+
 DC and CD1c
+
 DC by microarray (Fig. 4.4). Among the costimulatory 
molecules, we were able to detect upregulation of CD83 and CD40 on both DC subsets in response 
to all TLR treatments. R848 and the combination also induced TNFSF9 on both DC subsets, but 
upregulation was observed only on CD1c
+
 DC with poly IC. Steady state CD141
+
 DC had high 
expression level of ICOSLG and was further upregulated in response to R848 and the combination. 
In contrast, steady state CD1c
+ 
DC had low expression of ICOSLG and was upregulated in response 
to all treatments, but at lower level compared to the steady state CD141
+
 DC. CD70 and SLAMF1 
were selectively upregulated on CD1c
+
 DC with R848 and the combination. Interestingly, the R848 
and the combination also induced upregulation of co-inhibitory molecule, CD274, on both DC 
subsets which was not observed in response to poly IC. We also identified upregulation of 
costimulatory molecules that can induce both costimulatory and inhibitory signals. CD80 was 
upregulated on both DC subsets in response to R848 and the combination, but was also upregulated 
only on CD141
+
 DC with poly IC. Interestingly, CD86 was expressed at high levels on both DC 
subsets in the steady state and there was no further upregulation observed in response to any of the 
TLR treatments. Therefore, this shows that poly IC and R848 were capable of activating DC in vivo 
within 2hr and in particular R848 and the combination induced the highest upregulation of 
costimulatory molecule genes compared to poly IC. 
Next we determined if the surface expression levels of costimulatory molecules was also 
upregulated on all DC subsets after 2hr stimulation with poly IC or R848 or the combination in vivo. 
The surface expression of CD80, CD83, CD86 and CD40 molecules on freshly isolated DC, 2h post 
injection with TLR ligand, was measured by flow cytometry (Fig. 4.5A). The fold increase was 
calculated relative to the MFI of the matched isotype control. Interestingly there was no 
upregulation in cell surface levels of CD80, CD83, CD86 and CD40 molecules on all DC subsets 
within 2hr, which was comparable to the untreated mice (Fig. 4.5B). However there was a minor 
upregulation of CD83 on pDC in response to R848 and poly IC/R848 combination. These data 
suggests that within the 2hr timepoint, the upregulation of costimulatory molecule genes can be 
observed but this was too early to detect protein expression of costimulatory molecules on DC 
subsets in response to poly IC and R848 in vivo.  
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Figure 4.4: Modulation of costimulatory and co-inhibitory molecule genes on human DC 
subsets upon stimulation with TLR ligands in vivo. Expression level of selected costimulatory 
and co-inhibitory molecule genes on CD141
+
 DC and CD1c
+
 DC after 2hr in vivo stimulation with 
poly IC, R848 or the combination. Y-axis represents the signal intensity in log2 scale. The data 
represent the mean±SEM of 2 to 3 replicates is shown for each DC subset/stimulus. Grey dotted 
line represents the threshold detection level (<3.6). C: Untreated, P: poly IC, R: R848, PR: poly IC 
and R848. 
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Figure 4.5: Maturation of human DC subsets upon stimulation with TLR ligands in vivo. (A) 
Expression of DC maturation markers (CD80, CD83, CD86, and CD40) by freshly isolated CD141
+
 
DC, CD1c
+
 DC and pDC after 2hr stimulation with poly IC, R848 or the combination in vivo. One 
representative of two donors is shown in histograms. Red tint: Untreated, Blue: poly IC, Green: 
R848, Black: poly IC and R848 combination. (B) The fold increase in MFI of costimulatory 
molecules (CD80, CD83, CD86, CD40) on CD141
+
 DC, CD1c
+
 DC and pDC. The fold increase in 
MFI was calculated relative to isotype control for two donors are shown. Each symbol represent 
individual mice and the same symbol denotes mice from the same litter injected with the same 
CD34
+
 cells.  
4.2.7 Poly IC and R848 induce the production of cytokines and chemokines by human DC in 
vivo 
We examined the gene expression profiles of cytokines and chemokines of CD141
+
 DC and CD1c
+
 
DC, 2hr after injection with poly IC or R848 or the combination. We observed high upregulation of 
genes encoding the cytokines and chemokines for both CD141
+
 DC and CD1c
+
 DC (Fig. 4.6A). All 
treatments were capable inducing upregulation of TNF, IL1B, CCL5, CXCL9 and CXCL10 on both 
DC subsets. IL28A (IFNλ2), IL28B (IFNλ3), IL29 (IFNλ1) was specifically upregulated on 
CD141
+
 DC with poly IC, which was further upregulated with the combination. However, there was 
also minor upregulation of IL28A (IFNλ2), IL28B (IFNλ3), IL29 (IFNλ1) on CD1c+ DC in 
response to R848 and/or the combination. In contrast, IL6 was specifically upregulated on CD1c
+ 
DC in response to poly IC, but the R848 and the combination were capable of upregulating IL6 on 
both DC subsets. Notably, R848 and the combination were also capable of inducing upregulation of 
IFNA2 and IL27 on both DC subsets that was not expressed with poly IC. In addition, IL23A was 
selectively upregulated on CD1c
+
 DC, not detected on CD141+ DC, only in response to the R848 
and the combination. There was little or no expression level of IFNA1, IL12A/B and CXCL11 on 
both DC subsets even after TLR treatments. Interestingly, there was high basal expression level of 
IL10 and IL18 on both DC subsets and no further upregulation was observed after stimulation with 
poly IC and R848. 
To determine the functional response of human DC subsets to TLR ligands in vivo we measured the 
level of cytokines and chemokines in the serum, 2hr after injection with poly IC, R848 or the 
combination. Poly IC alone induced very low level of cytokines and chemokines, with exception of 
CXCL10 and IFNλ (Fig. 4.6B). The level of CXCL10 was over the detection limit in response to 
R848 and the combination. The measurement of CXCL10 needs to be repeated using diluted serum 
samples to obtain accurate level of this chemokine. The level of IFNλ was also detected in response 
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to the combination but little or no production was observed for R848. We observed high level 
(>5000ng/ml) of IFNα, TNFα, IL-6 and CXCL10 in response to R848 and the combination (Fig. 
4.6B). There was low level (<100ng/ml) of IL-1β, IL-10, IL-18 and IL-23 in response to all TLR 
treatments. Overall we observed higher amounts of cytokines and chemokine produced in response 
to the combined poly IC and R848 compared to the single TLR ligand. In addition, previous studies 
have reported synergistic effect by TLR ligands that enhanced cytokine production (158, 217). 
Although it did not reach significance, we observed a trend in the enhanced production of IL-12p70, 
IL-6, IL-27, IFNλ and CXCL11 in response to the combination compared with single TLR ligand 
(Fig. 4.6B). The in vivo study has demonstrated the potential of TLR ligands to induce human DC 
activation and cytokine production in vivo. Furthermore, these data provide some evidence showing 
synergistic effect by the poly IC and R848 to enhance cytokine and chemokine production by 
human DC in vivo. 
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Figure 4.6: Cytokine and chemokine production upon stimulation with TLR ligands in vivo. 
(A) The expression level of cytokines and chemokines on CD141
+
 DC and CD1c
+
 DC after 2hr in 
vivo stimulation with poly IC, R848 or the combination. Y-axis represents the signal intensity in 
log2 scale. The data represent the mean±SEM of 2 to 3 replicates is shown for each DC 
subset/stimulus. Grey dotted line represents the threshold detection level (<3.6). C: Untreated, P: 
poly IC, R: R848, PR: poly IC and R848. (B) Secretion of selected cytokines and chemokines after 
2hr in vivo stimulation with with poly IC, R848 or the combination. Serums were isolated and used 
for beads-based detection of 13 different analytes. IFNλ level was measured using ELISA. Each 
symbol represent individual mice and the same symbol denotes mice from the same litter injected 
with the same CD34
+
 cells. 
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4.3 Discussion 
This study showed that DC subsets developing in humanised NSG-A2 mice closely resemble 
human blood DC as shown by each corresponding DC subsets sharing the core gene signatures and 
functional receptor profiles that have been validated to be expressed on CD141
+
 DC and CD1c
+
 DC 
in humans.  The development of mouse DC have been well characterised and identified several key 
transcriptional factors important for differentiating into the specific DC lineage. BATF3, ID2 and 
IRF8 is required for development of mouse CD8
+
 DC, whereas IRF4 and RELB is critical for 
development of mouse CD8
-
 DC (225). Transcriptionome analysis has been successful in 
identifying the human counterpart of these mouse DC subsets (75, 78). In concordance with 
previous studies, we identified high expression of transcriptional factors BATF3, ID2 and IRF8 on 
CD141
+
 DC, in contrast IRF4 was highly upregulated on CD1c
+
 DC (77, 79, 85). However unlike 
the mice, very little is known about the development of human DC. BATF3 silencing of humanised 
mice was not sufficient in impairing the development of CD141
+
 DC which suggested other factors 
compensate sufficiently to maintain CD141
+
 DC development (226). There is also evidence 
showing mouse CD8
+
 DC can develop by a BATF3 independent pathway (227). In humans, IRF8 
has been shown to be important for the development of both CD141
+
 DC and CD1c
+
 DC (228). 
This suggests that IRF8 may have a broader function in humans that is different to the mouse 
system. Further investigation on how these transcription factors affect the development of human 
DC will be beneficial to have better understanding of the DC ontogeny in the human system. 
We have identified CD141
+
 DC and CD1c
+
 DC based on the phenotypic markers HLA DR, 
CD141/BDCA3 and CD1c/BDCA1. In agreement with previous study, we observed CLEC9A and 
CADM1 to be exclusively expressed on CD141
+
 DC and SIRPα and ITGAM (CD11b) to be 
specifically expressed on CD1c
+
 DC (176). The markers CLEC9A, SIRPα and ITGAM (CD11b) 
have been demonstrated to be additional markers that can be used to distinguish between these 
human DC subsets (84). Unexpectedly, we could not detect any expression of XCR1 on CD141
+
 
DC and DEC205 on both DC subsets developed from humanised NSG-A2 mice, which are 
expressed by their human counterpart (74, 85, 222). The probe used for detecting DEC205 on the 
Illumina platform was identified not to be specific for DEC205, which could explain the reason 
DEC205 could not be detected.  Possibly the probe for XCR1 may not bind to the coding region of 
XCR1 gene. We have also identified differential gene expression of several functional receptors 
between DC subsets. Similar to their human counterpart, CD141
+
 DC from humanised NSG-A2 
mice highly expressed CLEC1A (159), CLEC9A (85) and CXCR3 (85) compared to CD1c
+
 DC. 
CLEC7A was also highly expressed on CD141
+
 DC compared to CD1c
+
 DC, but a previous study 
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has reported comparable expression level between human CD141
+
 DC and CD1c
+
 DC (213). We 
have also identified high expression of CLEC14A on CD141
+
 DC which has not been previously 
characterised on this DC subset. In contrast, CD1c
+
 DC highly expressed CLEC4A (75, 159), 
CLEC10A (76, 213), CD302 (75), CCR2 (213), CX3CR1 (213) and IL13RA1 (159) compared to 
CD141
+
 DC. The TLR expression profile was found to be very similar to their human counterpart 
(79, 81, 229). CD141
+
 DC expressed TLR1, 3, 6, 7, 8 and 10, whereas CD1c
+
 DC expressed TLR1, 
4, 5, 6, 7, 8 and 10. As expected neither DC subset expressed TLR9 which is known to be 
exclusively expressed on pDC (81, 84). The over-representation pathway analysis have identified 
the NLR signalling and inflammasome pathways to be significantly over-represented based on 
differentially expressed genes (CARD9, CASP1, CASP4, NLRP3 and NOD2) that were highly 
upregulated on CD1c
+
 DC. Activation of the NLRP3 inflammasome promotes production of 
proinflammatory cytokines IL1β and IL-18 (230). This may suggest that CD1c+ DC are capable of 
producing these proinflammatory cytokines in a NLRP3 inflammasome dependent manner, which 
have not been previously characterised.  
This study shows that both DC subsets were capable of responding to TLR3 ligand, poly IC, and 
TLR7/8 ligand, R848 either alone or in combination. The transcriptome analysis has demonstrated 
that poly IC upregulated gene expression of CD83 and CD40 on both DC subsets with 2h 
stimulation in vivo. In contrast, the R848 and the combination induced upregulation of many 
different costimulatory molecule genes (CD80, CD83, CD40, TNFSF9 and ICOSLG) on both DC 
subsets after 2h post injection with R848 and the combination. CD141
+
 DC had high basal 
expression level of ICOSLG, which was similarly observed on human CD141
+
 DC from BM and 
peripheral blood from previous study (83). There was also subset specific upregulation of 
costimulatory molecules. Interestingly CD70 and SLAMF1 were selectively upregulated on CD1c
+
 
DC in response to R848 and the combination. Differential expression of CD70 has been previously 
found to be selectively upregulated on CD141
+
 DC with poly IC alone, but there was no 
upregulation observed on CD1c
+
 DC in response to either poly IC or R848 (212). Despite observing 
upregulation of costimulatory molecule genes, there was little or no upregulation of costimulatory 
molecules (CD80, CD83, CD86 and CD40) expressed on the surface of all DC subsets, 2hr after in 
vivo TLR stimulation. Interestingly there was upregulation of CD83 on pDC with R848 and the 
combination. This may suggest that pDC can respond quicker to the TLR stimulation compared to 
myeloid DC subsets. A previous study has demonstrated slow kinetics of DC activation in vivo that 
maximally activated costimulatory molecules at 11 to 14hr post injection with poly ICLC (150). 
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This indicates that the 2hr timepoint was most likely too early to observe any upregulation of these 
costimulatory molecules on DC.  
The TLR ligands were also capable of inducing upregulation of gene expression of cytokines and 
chemokines by DC subsets. There was selective upregulation of IFNλ encoding genes IL28A 
(IFNλ2), IL28B (IFNλ3) and IL29 (IFNλ1) on CD141+ DC with poly IC and further upregulated in 
response to the combination but could not be detected with R848 alone. IFNλ is a recently 
identified type III IFN that exerts anti-viral effects and more importantly promotes Th1 responses 
and significantly increases cytotoxic activity of CD8
+
 T cells (231, 232). We observed production 
of IFNλ in response to poly IC and the combination in vivo which confirms with the transcriptomic 
analysis. It has been well established that human CD141
+
 DC produce high level of IFNλ 
production in response to poly IC (54, 212). Interestingly there was no production of IFNα in 
response to poly IC, but a high level of IFNα was observed with R848 and the combination in vivo. 
This was also supported by transcriptomic analysis, which we observed upregulation of IFNA2 on 
both DC subsets only in response to R848 and the combination. A previous study has demonstrated 
production of IFNα in response to poly ICLC and R848 alone using humanised mice (150). The 
same study has also determined the kinetics of IFNα production in response to poly ICLC in vivo at 
which detectable levels were observed at 8hr and peaked at 11hr after injection. This may suggest 
that R848 stimulates a fast kinetics of IFNα production and possibly the 2hr timepoint is too early 
for IFNα levels to be detected in response to poly IC. We also observed upregulation of chemokines 
CCL5, CXCL9 and CXCL10 gene expression on both DC subsets in response to poly IC and R848. 
Surprisingly the CXCL11 gene expression could not be detected, which has been reported to be 
upregulated on both CD141
+
 DC and CD1c
+
 DC in response to poly IC (212). This could be due to 
the probe binding to the noncoding region of the CXCL11. Previous studies have demonstrated poly 
IC and R848 induce synergistic effects on IL-12 production on human DC (158, 217). We have also 
observed a trend showing enhanced production IL-12p70, IL-6, IL-27 and IFNλ in response to the 
combined poly IC and R848 compared to the single TLR ligand in vivo.  
In summary, our results demonstrated that CD141
+
 DC and CD1c
+
 DC developed in the humanised 
mice were phenotypically and functionally similar to their human blood counterparts. Further 
validation of the microarray results is required by real time PCR. The overrepresentation pathway 
analysis identified novel DC function by CD1c
+
 DC that was associated with NLR signalling and 
inflammasome pathways. We have identified differentially expressed genes on CD141
+
 DC and 
CD1c
+
 DC that have not been previously described and further follow up studies on their role in DC 
function is required. We also demonstrated the potential of using TLR ligand combination that 
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show synergistic effects of cytokine production and were capable of activating CD141
+
 DC and 
CD1c
+
 DC. This data suggest that combination of poly IC and R848 might be the effective adjuvant 
for optimal activation of both DC subsets.  Therefore this study has validated the humanised NSG-
A2 mice that can be used as a model for studying human DC function and also for evaluating novel 
DC adjuvants.   
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Chapter 5: Comparison of the T cell priming capacity between human DC subsets 
5.1 Introduction 
DC are widely recognised as the most efficient APC with unique abilities to attract and stimulate 
naïve CD4
+
 and CD8
+
 T cells (233). It is now well established that DC are a heterogeneous 
population composed of numerous subsets that can be distinguished by their phenotype, location, 
and functional properties. Due to their remarkable ability to stimulate T cells, DC have become 
attractive therapeutic targets for the cancer and infectious diseases fields. Indeed, induction of CD8
+
 
T cell response is absolutely critical in the control and eradication of tumour and pathogen infection 
(234-237).  DC subsets and their CD8
+
 T cell priming capacity have been well characterised in the 
mouse system. In the mouse, the major DC subset that induces optimal CD8
+
 T cell priming are 
CD8
+
 DC (47, 238). However in the human system, there is some controversy as to whether the 
CD141
+
 DC, the human counterpart of mouse CD8
+
 DC, would be most potent in inducing CD8
+
 T 
cell responses (93, 94). Many studies on human DC subsets have used assays that involves 
reactivation of memory responses using T cell lines that are highly enriched for Ag-specific CD8
+
 
memory T cells (74, 79, 98). Memory T cells are less dependent on costimulatory signals that may 
not be suitable to accurately measure the intrinsic ability of DC subsets to prime CD8
+
 T cells (239, 
240). In contrast, naïve T cells are highly dependent on the costimulatory signals (241, 242), which 
would provide more physiologically relevant test bed for DC comparison. 
Furthermore, as an indicator of antigen presentation, generally T cell responses have been 
characterised based on the frequency of IFNγ producing T cells (74, 79, 94, 243). There is now 
evidence showing that T cells are in fact polyfunctional, defined as the ability to simultaneously 
secrete multiple cytokines (71). Measuring only single function of T cells (e.g IFNγ production) 
does not describe their full potential and would result in an incomplete interpretation of their 
functionality (244). Multi-parameter flow cytometry can be utilised to characterise multiple 
functions simultaneously on a single cell basis to provide a much better understanding T cell 
“quality” and is more comprehensive analysis to assess the capacity of DC subsets to prime CD8+ T 
cells (114).   
CB is a rich source of haematopeitic cells and is comprised chiefly of T cells of naïve phenotype 
(CD45RA
+
) (245, 246). The ability to combine human DC subsets from the humanised mice and 
autologous T cells from the same cord blood donor is very attractive test system that can be used to 
compare the intrinsic ability of human DC subsets to activate naïve CD8
+
 T cells in an Ag-specific 
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fashion. This will be the first comparative study to analyse the ability of specific human DC subsets 
to activate naïve CD8
+
 T cells.  
5.2 Results 
5.2.1 Poly IC and R848 combination induced maturation, cytokine and chemokine production 
by DC in vitro 
To determine if the poly IC and R848 combination can induce upregulation of the surface 
expression of costimulatory molecules on DC, we have isolated DC subsets from humanised mice 
and stimulated with poly IC and R848 combination in vitro for 18hr. The freshly isolated DC had 
no expression of CD80, CD83, CD86 and CD40 molecules which shows immature phenotype (Fig. 
5.1A, B). We observed spontaneous upregulation of CD83 and CD86 on CD141
+
 DC and CD1c
+
 
DC after 18hr culture in the absence of TLR ligands (medium alone). CD83 (in some donors) and 
CD86 was further upregulated on CD141
+
 DC and CD1c
+
 DC following combined poly IC and 
R848 stimulation (Fig. 5.1B). In contrast, pDC did not express CD83 and CD86 after 18hr culture 
in the absence of TLR ligands, but was upregulated following combined poly IC and R848 
stimulation. Interestingly, the spontaneous upregulation of CD83 on CD141
+
 DC was significantly 
higher than pDC activated with the combined TLR ligands (Fig. 5.1B). CD141
+
 DC also expressed 
significantly higher level of CD80 compared to pDC and had significant higher expression of CD86 
than CD1c
+
 DC after stimulation with the combined TLR ligands (Fig. 5.1B). The level of CD40 
upregulation was comparable between DC subsets after stimulation with the combined TLR ligands. 
Therefore the combination of poly IC and R848 was capable of activating all DC subsets. 
74 | P a g e  
 
  
 
75 | P a g e  
 
Figure 5.1: Maturation of human DC subsets upon stimulation with TLR ligands in vitro.  (A) 
Expression of DC maturation markers (CD80, CD83, CD86, and CD40) by CD141
+
 DC, CD1c
+
 DC 
and pDC freshly isolated (0h) or  after 18hr culture in complete medium alone or in the presence of 
poly IC and R848. One representative of three donors is shown in histograms. Red: isotype control 
Blue: test (B) The fold increase in MFI of costimulatory molecules (CD80, CD83, CD86, CD40) on 
CD141
+
 DC, CD1c
+
 DC and pDC. The fold increase in MFI was calculated relative to isotype 
control for three donors are shown. Each symbol represent individual mice and the same symbol 
denotes mice from the same litter injected with the same CD34
+
 cells. * P < 0.05 by Kruskal-Wallis 
test. 
 
We next measured the level of cytokines and chemokines produced by each human DC subsets in 
response to poly IC and R848 combination. All human DC subsets were capable of producing both 
cytokines and chemokines. The production of IFN-λ was restricted to CD141+ DC. All DC subsets 
produced TNFα, IL-6 and IL-12p70 but CD1c+ DC produced the largest amount of these cytokines 
(Fig. 5.2). CD1c
+
 DC also produced IL-1β and IL-10 which was not detected by CD141+ DC. This 
suggests CD1c
+
 DC is a major producer of IL-1β and IL-10. The level of IL-18 and IL-27 was 
undetectable for all DC subsets. pDC are known to be a major producer of IFNα in response to viral 
infection. However we observed very low amount of IFNα from pDC and undetectable level from 
CD141
+
 DC and CD1c
+
 DC. CD141
+
 DC was also capable of producing higher level of chemokines 
which include CCL5 and CXCL9 compared to other DC subsets. This suggests CD141
+
 DC is a 
potent chemokine producing cells that may play important role in recruiting T cells.  
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Figure 5.2: Cytokine  production by human DC subsets upon stimulation of TLR ligands in 
vitro. DC subsets were isolated from the BM of humanised NSG-A2 mice. The cytokine and 
chemokine levels in the 18hr DC culture in complete medium alone or in the presence of poly IC 
and R848 (PIC/R848). The cytokine and chemokine levels in the serum were determined using bead 
based immunoassays. IFNλ level was measured using ELISA. Data from 4 independent 
experiments are shown. 
 
 
 
 
77 | P a g e  
 
5.2.2 Direct presentation by DC induced increased Ag-specific CD8
+
 T cells 
To first compare the intrinsic ability of each DC subsets to prime naïve CD8
+
 T cells, we analysed 
the proportion of Ag-specific CD8
+
 T cells through multimer staining. As a model Ag we have 
selected MART-1 (ELAGIGILTV, ELA peptide) HLA-A*02:01-restricted peptide from a human 
melanoma associated Ag that is widely used in tumour immunotherapy (247, 248). There is a high 
precursor frequency of naive CD8
+
 T cells against ELA peptide found in the CB (249). This allows 
direct identification and isolation of Ag-specific naive CD8
+
 T cells that can be used as responders 
for T cell priming. We first isolated three DC subsets from FLT3-L treated humanised mice, these 
DC were then pulsed for 2hr with MART-1 ELA peptide in the presence of TLR3 ligand poly IC 
and TLR7/8 ligand R848. DC were then cultured with pure, autologous  CB-derived naïve CD8
+
 T 
cells for 21 days in vitro. Ag-specific T cells among the total CD8
+
 T cells were enumerated using 
HLA-A2- ELA pentamer staining (Fig. 5.3A). All DC subsets had the capacity to induce 
proliferation of Ag-specific CD8
+
 T cell up to an impressive 26% (Fig. 5.3B). It was found that the 
percentage of pentamer
+
 cells were overall higher after incubation with CD141
+
 DC compared to 
other DC subsets, which was statistically significant when CD141
+
 DC compared with CD1c
+
 DC 
(Fig. 5.3B). Next, we measured the mean fluorescence intensity (MFI) of the pentamer
+
 cells which 
determines the amount of TCR on the cell surface. Similarly T cells incubated with CD141
+
 DC 
demonstrated higher MFI than other subsets and this was statistically significant when compared to 
pDC (Fig. 5.3C). Collectively, the data suggests that CD141
+
 DC were able to induce higher 
proliferation of Ag-specific T cells and induce higher sensitivity for the MART-1 ELA peptide 
compared to other DC subsets.  
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Figure 5.3: Enhanced naïve priming of Ag-specific T cells from specific DC subsets. Purified 
humanised BM derived DC subsets (CD141
+
 DC, CD1c
+
 DC and pDC) were pulsed with MART-1 
ELA peptide for 2hr in the presence of poly IC and R848. DC were washed and cocultured with 
autologous CB-derived naïve CD8
+
 T cells for 21 days. At day21, the frequency of Ag-specific T 
cells were enumerated using pentamer staining (MART-1 ELA pentamer). (A) Representative 
gating strategy to identify Ag-specific CD8
+
 T cells. CD8
+
 T cells were gated from non–lineage 
(CD14, CD19), live cells (dead cells were stained with Live Dead Aqua) and further gated based on 
the expression of CD3 and CD8. Difference in the percentage (B) and MFI (C) of pentamer
+
 cells in 
total CD8
+
 T cells after being cocultured with different DC subsets for 21 days.  Each dot represents 
an individual donor and the connected dots are from the same donor. *P = 0.02 by Wilcoxin signed-
ranked test. 
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5.2.3 DC subsets primed Ag-specific CD8
+
 T cell populations with polyfunctional profiles.  
Given the differences in the ability of DC subsets to prime absolute numbers of Ag-specific T cell 
responses, we next asked whether different DC priming strategies resulted in differences in T cell 
“quality”. Here the quality of CD8+ T cells was evaluated by performing multifunctional 
intracellular staining (ICS). For these experiments, CD8
+
 T cells from 21 day DC cultures were 
restimulated with MART-1 ELA peptide for 6hr in the presence of brefeldin A and golgi stop. 
Polychromatic flow cytometry was then performed to identify of CD8
+
 T cells that secreted 
individual and combinations of the follow Th1 cytokines and degranulation markers: surface 
CD107a (degranulation marker), TNFα, IFNγ, IL-2 (Fig. 5.4).  
 
 
Figure 5.4: Analysis and quantification of polyfunctional Ag-specific T cell responses from DC 
primed cultures. CD8
+
 T cells were gated from CD4
-
 live cells. CD8
+
 T cells were further gated 
for individual function:  surface CD107a (degranulation), intracellular TNFα, IL-2 and IFNγ. 
Boolean gating was performed to determine the frequencies of each unique combination of 
functions. Data was generated from flow Jo was then analysed on SPICE software. 
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The total CD8
+
 cell response was calculated by summing the frequencies of each unique 
combination of functions. However there was no difference in the percentage of total CD8+ T cell 
response between the DC subsets (Fig. 5.6A). The most common function was CD107a and TNFα 
in which large proportion of responding CD8
+
 T cells (>60% of pentamer
+
 cells) produced these 
cytokines (Fig. 5.5 and 5.6B). There was low frequency of IL-2 secreting T cells which contributed 
less to the total Ag-specific response. 
Combination measurements of multiple functions by CD8
+
 T cells provided a more detailed 
assessment of the T cell quality. We observed a higher proportion of T cells with 2 functions and 3 
functions in Ag-specific T cells (Fig. 5.5 and 5.6C). The majority of polyfunctional cells were triple 
positive for CD107a, TNFα and IFNγ. Interestingly, IFNγ was predominatly expressed within 
polyfunctional T cells and not often observed in monofunctional T cells (Fig. 5.5).  Furthermore, 
nearly all of the IFNγ producing CD8+ T cells also expressed CD107a. This suggests that majority 
of the IFNγ producing CD8+ T cells have cytotoxic activity. When comparing each DC subsets for 
their contribution to the polyfunctional T cells response, CD141
+
 DC had a higher trend for 
polyfunctional T cells but were very similar compared to CD1c
+
 DC (Fig. 5.5). Overall there was 
no significant difference in the functional pattern of CD8
+
 T cells when analysing in single or multi 
dimensions.  
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Figure 5.5: Quantification of polyfunctionality of Ag-specific CD8
+
 T cells primed with DC 
subsets. Functional profiles of CD8
+
 T cell response stimulated with different DC subsets and 
challenged with MART-1 ELA peptide. Each unique combination of functions (CD107a, IFNγ, IL-
2, and TNFα) is displayed on the x axis. The responses are grouped and colour coded according to 
number of functions. The data are summarized in a pie chart form where each pie slice represents 
the mean proportion of the total CD8+ T cell response that have 4 (red), 3 (orange), 2 (green) or 1 
(blue) of the measured functions.  The data represents the average of 5 donors. 
 
82 | P a g e  
 
 
Figure 5.6: Similar functional patterns of Ag-specific CD8
+
 T cells primed with different DC 
subsets. (A) Total CD8
+
 T cell response against MART-1 ELA peptide. The bars indicates 
mean±SEM. (B) The proportion of each function within the total CD8+ T cell response. The 
frequency of CD8+ T cells expressing each function was divided by the total CD8
+
 T cell response. 
(C) Frequency of CD8
+
 T cells with different number of functions. Box represents median and 
interquartile range. Data represent 5 independent experiments from 5 individual donors. 
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A key factor in assessing the quality of the T cell response is the amounts and combinations 
cytokines produced by DC-activated T cells after Ag engagement. Previous studies have reported 
that the amount of cytokine produced can be estimated based by the MFI of the staining of cytokine 
(104, 106, 107, 114). Using this approach, we have determined the MFI of IFNγ and TNFα and 
examined correlations with other functional combinations. Similar to previous studies, we have 
observed a correlation between IFNγ (104, 106) and TNFα (104) MFI and number of functions.  
Monofunctional CD8
+
 T cells exhibited very low MFI for IFNγ and TNFα (Fig. 5.7). The MFI of 
these cytokines gradually increased as the number of functions expressed by T cells increased.  This 
suggests that polyfunctional T cells produce more cytokine per cell compared to monofunctional T 
cells. Quantitatively, we found that a single polyfunctional CD8
+
 T cell, which expresses all 
functions, made between 8-10 fold more IFNγ and 10-14 fold more TNFα compared with 
monofunctional CD8
+
 T cells. However, when comparing the effect of DC subsets on the 
magnitude of cytokine production, the MFI of these cytokines were very similar. Therefore there 
was no obvious advantage of one particular DC subset over another in altering the functional status 
of Ag-primed T cells.  
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Figure 5.7: Polyfunctional T cells secrete higher amount of IFNγ and TNFα per cell than 
monofunctional T cells. The MFI of IFNγ and TNFα expressing CD8+ T cells were compared with 
other functional outputs from 5 independent donors. The bars represent the mean±SEM. The x-axis 
represents all specific functional combinations that secrete IFNγ or TNFα. C: CD107a, T: TNFα, G: 
IFNγ and 2: IL-2 
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5.3 Discussion 
Improvement of DC based immunotherapy against tumour and infectious diseases will require 
detailed understanding of the interaction between DC and T cells. This study was undertaken to 
explore this cell:cell relationship using humanised mice. Importantly, this is the first study to 
directly compare the ability of all 3 human DC subsets (CD141
+
 DC, CD1c
+
 DC and pDC) to prime 
naïve CD8
+
 T cells in an Ag-specific manner.  
In vitro stimulation (18h) of DC subsets with poly IC and R848 combination demonstrated 
upregulation of CD80, CD83, CD86 and CD40 in all DC subsets. Overall, CD141
+
 DC was most 
activated compared to other DC subsets after 18hr stimulation with poly IC and R848 combination 
in vitro. Highly activated nature of CD141
+
 DC may contribute to their capacity to prime CD8
+
 T 
cells, which suggest a potential target for DC based immunotherapy.  
We demonstrated that poly IC/R848 activated DC subsets from humanised mice have the ability to 
present Ag to naïve CD8
+
 T cells and induce expansion of MART-1-specific CD8
+
 T cells in vitro. 
We observed a higher percentage of pentamer
+
 CD8
+
 T cells when stimulated with CD141
+
 DC 
compared to CD1c
+
 DC and pDC. This suggests that absolute numbers of Ag-specific T cells tends 
to be highest when antigen presentation was mediated by CD141
+
 DC. Furthermore, the MFI of the 
MART-1 pentamer staining was similar when stimulated with CD141
+
 DC and CD1c
+
 DC but was 
much higher compared to pDC. Previous studies have shown that the MFI of pentamer staining 
correlated with increased TCR affinity, i.e the strength of the interaction between TCR and MHC 
complex (69, 250). Thus, this new data indicates that CD141
+
 DC and CD1c
+
 DC have the ability to 
expand T cells with higher affinity TCRs against MART-1 peptide compared to pDC. Indeed, it has 
been previously reported that there is a direct correlation between TCR affinity/avidity and T cell 
function but there is a defined natural threshold at which T cell function cannot be further impoved 
(70-72, 251).  
Traditionally, the standard in evaluating the efficiency of Ag-specific CD8
+
 T cell responses is 
measured by IFN-γ production via ELISPOT assay or ELISA. While the approach of using a single 
marker (ie IFN-γ) can be used to determine a magnitude of response, the simultaneous measurement 
of multiple markers (multiple effector functions) provides a much more in depth analysis to define 
the “quality” of the response.  There is evidence that the quality of T cell response is crucial in 
determining the disease outcome (114). Polyfunctional T cells, which have multiple effector 
functions in response to Ag, have been demonstrated to show good correlation with improve 
clinical outcome (104-107, 252). It has been reported that bias towards monofunctional T cells has a 
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negative effect on immunity and correlated with disease progression (253, 254). The positive 
attributes of polyfunctional T cells is most likely due to the ability to secrete multiple cytokines that 
enables greater number of functions to activate multiple cell lineage and cellular pathways. These 
synergistic effects most likely lead to an improved immunosurveillance and improved immune 
response.  
In this study, Boolean gating was used to enumerate the frequency of all possible cytokine 
combinations produced by T cells on a single cell basis. This strategy provides in-depth functional 
analysis of single T cells and enables better comparison of the intrinsic ability of each DC subset to 
prime naïve CD8
+
 T cells and convert them into effector cells.  We found that all DC subsets were 
capable of inducing both monofunctional and polyfunctional MART-1-specific CD8
+
 T cells 
producing degranulation (CD107a expression) and secretion of IFN-γ, TNF-α and IL-2. 
Interestingly, similar to the pattern observed in the MFI of the pentamer
+ 
cells, there was a trend for 
more polyfunctional responses observed from T cells stimulated with CD141
+
 DC and CD1c
+
 DC 
compared with pDC. This is a notable observation given a study that demonstrated a positive 
correlation between the TCR affinity and T cell polyfunctionality (71).  
 
Previous studies have demonstrated that not only do polyfunctional T cells have multiple effector 
functions but they also secrete a greater quantity of cytokines compared with monofunctional T 
cells (104, 106, 114). We also observed a similar correlation where cells with 5 functions produces 
15−20 fold more IFN-γ and TNF-α than cells that have only one function. This pattern was not 
observed for IL-2 that is in agreement with previous studies (104, 106). The molecular mechanisms 
behind this phenomenon are not well understood. Overall, polyfunctional Ag-specific T cells are 
highly potent effectors, as they are individually capable of producing increased quantities of 
multiple effector molecules.  
 
Collectively, we clearly showed that human DC subsets are capable of priming naïve CD8
+
 T cells 
to induce an Ag-specific immune response. We have demonstrated that DC subsets induced both 
single and multiple immune mediators by CD8
+
 T cells against MART-1 peptide. Based on this 
data, there is some evidence suggesting that CD141
+
 DC are superior at priming CD8
+
 T cells as 
shown by increased absolute numbers of MART-1-specific CD8
+
 T cells with highly polyfunctional 
profiles (IFNγ, TNFα, IL-2 and CD107a). This study has also shown that the multiparameter flow 
cytometric assay provides a much more detailed assessment of the quality of the T cell response 
induced by human DC subsets compared to the conventional single parameter readouts. Therefore, 
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the quality of the T cell responses needs to be addressed when comparing the CD8
+
 T cell priming 
by human DC as it provides critical information associated with protective immunity. 
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Chapter 6: Conclusion and future directions 
This study investigated and validated the use of humanised NSG-A2 mice as a relevant model for 
DC based immunotherapy. The first aim of this study was to optimise the generation of humanised 
mouse model and investigate what cell types have differentiated from the cord blood derived CD34
+
 
HSC. Since the number of CD34
+
 cells is a major limiting factor due to restricted access to cord 
blood, initial experiment focused on identifying the minimum CD34
+
 cell dose that could achieve 
stable engraftment of human HSC. We observed improvement in engraftment level that was 
correlated with the number of CD34
+
 cells injected and found 2x10
5
 CD34
+
 cells to be the ideal cell 
dose to obtain consistent stable human engraftment in NSG-A2 mice. Important characteristic of 
humanised mouse model is the ability to support wide range of human immune cells establishing a 
human immune system. We were able to identify various cell subsets which include B cells, T cells, 
monocytes and all DC subsets (CD141
+
 DC, CD1c
+
 DC and pDC) in lymphoid and non-lymphoid 
organs. However the proportion of cells within humanised mice was different to those found in 
humans (203, 204). We observed a bias in the differentiation of HSC towards B cells and less 
development of monocytes in humanised NSG-A2 mice. Previous study has generated novel mouse 
strain expressing human cytokines (TPO, IL-3, M-CSF and GM-CSF) to demonstrate the 
importance of expressing human cytokines for the development of innate immune cells, in 
particular monocytes (178). This suggests that the humanised NSG-A2 mouse model is not suitable 
for functional characterisation of monocytes due to lack of these human cytokines that facilitate in 
their development as well as their function. In contrast, the humanised NSG-A2 mice is a suitable 
model for generating human DC, which does not require these additional human cytokines/factors 
for their development and functions.  
The development of human DC subsets was confirmed in the humanised NSG-A2 mice, we then 
investigated if these DC subsets closely resemble human blood DC subsets. This is very critical to 
allow direct translation of results obtained from humanised mice to humans. Comparative 
transcriptomic analysis of mouse and human DC subsets has confirmed the existence of homologies 
between species (75, 78). Previous studies have identified conserved gene signatures that enable 
identification of human DC subsets (75, 79, 84, 85, 159, 213, 219). It is evident from the 
transcriptome analysis that CD141
+
 DC and CD1c
+
 DC from humanised mice share common gene 
expression profiles, such as transcriptional factors, surface molecules and functional receptors, as 
their human blood counterparts (75, 85). Therefore we have demonstrated close alignment between 
DC subsets isolated from humanised NSG-A2 mice and their human counterpart. We also have an 
important reference microarray data set for CD141
+
 DC and CD1c
+
 DC, with and without TLR 
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activation (poly IC, R848 and the combination) in vivo. These datasets can be used to identify novel 
or unexplored genes with potential role in DC function. Similar approach can be used to explore the 
effect of novel adjuvants on human DC, new insights into the processes of DC activation and 
signaling pathways. There were 8 core gene signatures, which majority having unknown function 
on DC, expressed on CD141
+
 DC that overlapped with other transcriptome studies (75, 85). 
Targeted deletion of these unexplored genes on CD141
+
 DC and performing various functional 
assays (e.g. cytokine/chemokine production, T cell priming and Ag uptake) may determine their 
role in DC function. We also identified NLRP3 inflammasome pathway to be over-represented in 
the list of differentially expressed genes that were highly expressed on CD1c
+
 DC. Western blot 
analysis can be performed to validate the protein expression of NLRP3 inflammasome components 
(e.g. NLRP3, ASC, Caspase-1) on CD1c
+
 DC (255). To determine whether NLRP3 inflammasome 
activation is required for secretion of proinflammatory cytokines (IL-1β and IL-18) by CD1c+ DC, 
targeted deletion of genes encoding the NLRP3 inflammasome components can be performed. 
DC maturation involves upregulation of costimulatory molecules together with cytokine and 
chemokine production. TLR ligands are potent DC activator that are used as vaccine adjuvant (215). 
We have used poly IC, R848 alone or in combination to demonstrate the function of DC subsets 
from humanised mice. The use of humanised mouse model enables us to determine the effect of 
TLR ligands on DC in vivo. The effect of the combined TLR stimulation on human DC subsets in 
vivo is not well understood. We examined the phenotype of CD141
+
 DC, CD1c
+
 DC and pDC and 
found upregulation of costimulatory molecule genes upon stimulation with poly IC, R848 alone or 
in combination in vivo. However the 2hr timepoint was too early to observe any upregulation of 
costimulatory molecules expressed on the surface of DC. In contrast, we detected various cytokines 
and chemokines produced in this early timepoint. We observed a trend showing synergistic effect of 
the combined TLR stimulation that resulted in enhanced production of IL-12p70, IL-6, IL-27 and 
IFNλ. Detailed kinetics analysis of DC activation at different time points in response to TLR 
ligands will enable better understanding of their overall immunostimulatory capacity. We further 
investigated the effect of the poly IC and R848 combination on isolated human DC subsets in vitro. 
The surface expression of costimulatory molecules (CD80, CD83, CD86 and CD40) was most 
increased on CD141
+
 DC, whereas CD1c
+
 DC and pDC was activated to similar extent upon 
combined TLR stimulation. We observed differential cytokine and chemokine profile between DC 
subsets in response to the poly IC and R848 combination. CD141
+
 DC produced high levels of 
chemokines (CCL5, CXCL9 and CXCL10) and uniquely produced IFNλ. In contrast, CD1c+ DC 
produced high levels of IL-6, IL-10 and TNFα. The capacity to produce large amounts of IFNα is a 
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hallmark of pDC function, but we observed very low level of IFNα from pDC. Further investigation 
in the function of pDC is required using TLR9 ligand, CpG, to confirm its capacity to produce IFNα 
(256). Overall poly IC and R848 combination was capable of activating all DC subsets by inducing 
upregulation of costimulatory molecules together with cytokine and chemokine production that can 
be used further in this study.  
The ability of human DC subsets to prime CD8
+
 T cell has been the major focus to identify 
potential candidate for Ag delivery as therapeutic vaccines against cancer (1). Several comparative 
studies have demonstrated that CD141
+
 DC, CD1c
+
 DC and pDC have similar capacity to prime 
memory CD8
+
 T cells (93, 94). However it was not known whether there is any difference in the 
capacity to prime naïve CD8
+
 T cells by human DC subsets. We assessed in vitro the ability of DC 
subsets from humanised mice to prime naïve CD8
+
 T cells by flow cytometry. We demonstrated 
that poly IC/R848 activated DC subsets from humanised mice have the ability to present Ag to 
naïve CD8
+
 T cells and induce expansion of MART-1-specific CD8
+
 T cells in vitro. There was a 
higher percentage of pentamer
+
 CD8
+
 T cell when stimulated with CD141
+
 DC compared to CD1c
+
 
DC and pDC. There was a trend for more polyfunctional response (IFNγ, TNFα, IL-2 and CD107a) 
observed from T cells stimulated with CD141
+
 DC and CD1c
+
 DC compared to pDC. Therefore 
there is some evidence suggesting that CD141
+
 DC are superior at priming naïve CD8
+
 T cells as 
shown by increased absolute numbers of MART-1-specific CD8
+
 T cells with highly polyfunctional 
profiles (IFNγ, TNFα, IL-2 and CD107a). CD107a has been described as a marker of CD8+ T cell 
degranulation that is determined to be correlated with cytotoxic activity (120). However it is 
important to perform cytotoxicity assay to confirm if the CD8
+ 
T cells stimulated by DC subsets are 
able to kill target cells in an Ag-specific manner. Recent study have identified memory T cells with 
stem cell like properties, which have superior anti-tumour response compared to conventional 
memory T cells. Further investigation of the T cell phenotype following stimulation with different 
DC subsets will determine whether each DC subset have different role in dictating the fate decision 
between central memory, effector memory or stem memory T cell differentiation.  
Understanding the unique functional capabilities of human DC subsets in vivo is essential for 
rational design of DC based immunotherapy. Selective depletion of mouse CD8
+
 DC have 
demonstrated important role of CD8
+
 DC in CTL immunity (47). Future investigation by selectively 
depleting specific human DC subsets will provide insight into the cytokine and chemokine profiles 
of human DC subsets in response to poly IC and R848 in vivo. Another important step would be to 
investigate the capacity of human DC subsets to prime CD8
+
 T cells in vivo. Ag targeting has been 
extensively studied in mice, which shows potent cellular and humoral immunity (257-259). Ag 
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targeting can be utilised to specifically target human DC and determine the efficacy of this strategy 
in vivo using the humanised mice. There is also the potential to use humanised NSG-A2 mouse 
model to investigate how DC subsets modulate tumour growth.  
Overall, the validation of humanised NSG-A2 mouse model provides a powerful platform to 
understand functional attributes of human DC both in vitro and in vivo. These include DC 
maturation, cytokine and chemokine production, and CD8
+
 T cell priming. Humanised mouse 
model opens new opportunity to evaluate vaccine safety and immunogenicity that will aid in the 
design and development of effective vaccines.  
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Appendices 
Appendix 1: Abs, pentamer and dye 
Cell surface 
antigens 
Conjugate Isotype Clone Manufacturer 
CD3 Pacific blue Mouse IgG2a, κ OKT3 Biolegend 
CD3 PE Mouse IgG2a, κ HIT3a Biolegend 
CD3 BV605 Mouse IgG2a, κ OKT3 Biolegend 
CD4 FITC Mouse IgG1, k RPA-T4 BD Pharmingen 
CD4 BV711 Mouse IgG1, k SK3 BD 
CD8 FITC Mouse IgG1, k HIT8a Biolegend 
CD8 PE-Cy7 Mouse IgG1, k RPA-T8 Biolegend 
CD14 APC Mouse IgG1, k HCD14 Biolegend 
CD19 Pacific blue Mouse IgG1, k HIB19 Biolegend 
CD20 Pacific blue Mouse IgG2b, κ 2H7 Biolegend 
CD34 FITC Mouse IgG1, k 8G12 BD 
CD45 APC-Cy7 Mouse IgG1, k H130 Biolegend 
CD45 PerCP Mouse IgG1, k  BD 
mCD45 PerCP-
Cy5.5 
Rat IgG2b, κ 30-F11 Biolegend 
CD123 PE Mouse IgG1, k 9F5 BD 
CD123 PerCP-
Cy5.5 
Mouse IgG1, k 6H6 Biolegend 
CD141 APC Mouse IgG1, k M80 Biolegend 
CD1b/c FITC Mouse IgG1 B-B5 Abcam 
HLA DR PE-Cy7 Mouse IgG2a, κ L243 Biolegend 
CD107a FITC Mouse IgG1, k H4A3 BD 
Costimulatory 
molecules 
    
CD40 FITC Mouse IgG1, k 5C3 BD 
CD70 FITC Mouse IgG1, k 113-16 Biolegend 
CD80 FITC Mouse IgG1, k L307.4 BD 
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CD83 FITC Mouse IgG1, k HB15e BD 
CD86 FITC Mouse IgG1, k 2331(FUN-1) BD 
IgG1 FITC Mouse IgG1, k X40 BD 
Intracellular 
antigens 
    
TNFα APC Mouse IgG1, k Mab11 BD 
IFNγ PE Mouse IgG1, k 4S.B3 BD 
IL2 Alexa-700 Mouse IgG2a, κ MQ1-17H12 Biolegend 
Depletion Abs     
CD3 Unconjugate Mouse IgG1 UCHT1 Beckman 
Coulter 
CD14 Unconjugate Mouse IgG2a, κ RMO52 Beckman 
Coulter 
CD19 Unconjugate Mouse IgG1 J3-119 Beckman 
Coulter 
CD20 Unconjugate Mouse IgG2a B9H9(HRC20) Beckman 
Coulter 
CD34 Unconjugate Mouse IgG1, k MY10 BD 
mCD45 Unconjugate Rat IgG2b, κ 30-F11 BD 
TER-119/Erythroid 
Cells 
Unconjugate Rat IgG2b, κ TER-119 Biolegend 
Pentamer     
MHC/ 
ELAGIGILTV 
(MelanA / MART26-
35) pentamer 
APC - - ProImmune 
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Appendix 2: Summary of the RNA quality of the samples used for microarray experiment 
Cell 
subset Treatment 
Biological 
replicate 
Sample ID 
RNA conc. 
RIN 
Score 
cRNA 
conc. 
CD141 Untreated 1 3998755167_E 28ng/ul 8.9 284ng/ul 
CD141 Poly IC 1 3998755167_I 54ng/ul 9.2 245ng/ul 
CD141 R848 1 3998755167_B 92ng/ul 9.3 82 ng/ul 
CD141 Poly IC+R848 1 3998755167_A 126ng/ul 9.4 225ng/ul 
CD1c Untreated 1 3998755167_G 116ng/ul 9.4 356ng/ul 
CD1c Poly IC 1 3998755167_K 112ng/ul 9.2 151ng/ul 
CD1c R848 1 3998755167_D 62ng/ul 9.5 308ng/ul 
CD1c Poly IC+R848 1 3998755167_C 94ng/ul 9.7 31ng/ul 
CD141 Untreated 2 3998755167_J 62ng/ul 8.9 446ng/ul 
CD141 Poly IC 2 3998755170_A 64ng/ul 8.5 552ng/ul 
CD141 R848 2 3998755170_E 126ng/ul 8.6 309ng/ul 
CD141 Poly IC+R848 2 3998755167_F 70ng/ul 8.5 1329ng/ul 
CD1c Untreated 2 3998755167_L 60ng/ul 8.9 23ng/ul 
CD1c Poly IC 2 3998755170_C 110ng/ul 8.9 184ng/ul 
CD1c R848 2 3998755170_G 96ng/ul 8.7 523ng/ul 
CD1c Poly IC+R848 2 3998755167_H 104ng/ul 8.6 911ng/ul 
CD141 Untreated 3 3998755170_B 96ng/ul 8.9 1205ng/ul 
CD141 Poly IC 3 3998755170_F 130ng/ul 8.9 1375ng/ul 
CD141 R848 3 3998755170_J 104ng/ul 9.6 916ng/ul 
CD141 Poly IC+R848 3 3998755170_I 246ng/ul 8.4 289ng/ul 
CD1c Untreated 3 3998755170_D 114ng/ul 8.7 1100ng/ul 
CD1c Poly IC 3 3998755170_H 226ng/ul 9.6 156ng/ul 
CD1c R848 3 3998755170_L 164ng/ul 9.2 153ng/ul 
CD1c Poly IC+R848 3 3998755170_K 350ng/ul 9.1 323ng/ul 
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Appendix 3: Detection of outliers using boxplot and hierachial clustering methods. Boxplot 
and hierachial clustering was performed on pre-normalisation data using Lumi package.  
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Appendix 4: Summary of overlapping gene list that were significantly upregulated by CD141
+
 
DC and CD1c
+
 DC from humanised mice and their human blood counterpart  
DC subsets Genes 
 
 
 
CD141
+
 DC 
SEPT3; CLNK; FKBP1B; LRRC1; SNX22; GCSAM; CADM1; BTLA; ST7; 
RPAP3; FNIP2; CNN2; PPAP2A; DPP4; CLEC9A; TCEA3; PRKCZ; ASNS; 
KIF16B; LAG3; RAB11FIP3; TMEM14A; BIK; GRAP2; KIAA0226L; VAC14; 
TGM5; NCALD; PPY; CDK2AP1; SNX3; GPR126; NUP155; OSBPL9; KDSR; 
ENOX1; BATF3; WDFY4; PSEN2; CAMK2D; PTGES2; RGS10; CD226; 
FRMD4A; SH3RF2; GDPD5; ICOSLG; DHRS3; C1orf115; TDRD10; NDUFS4; 
GPER; CYYR1; FAM102A; PTK2; TUBB6; PAWR; KATNA1; CXCR3; ENPP1; 
PQLC2; DBN1; ZBED3; GFOD1; TSPAN33; NBEAL2; STX3; FUCA1; FGD6; 
FNBP1 
 
CD1c
+
 DC 
RTN1; COL9A2; CCR6; CD2; SDSL; GALM; PIP4K2A; DEPTOR; CD1E; 
FCER1A; TESC; CA2; ADAP1; CLEC4A; NCF2; CSF3R; CASP1; IGSF6; 
SLC7A7; CCL5; MS4A7; CD300A; CSF1R; SIRPA; CD302 
 
The list of genes upregulated on human blood CD141
+
 DC or CD1c
+
 DC were from two previous 
transcriptome studies (75, 85) 
